COVID Injections: Unveiling the Mechanisms of Harm

New pathology, a new wave of disease, and 44 common examples of injection-induced illnesses supported by over 930 scientific publications linking these diseases with the injections.

Introduction

The list of traditional diagnoses arising as sequel from the COVID-19 genetic injections is extensive. Pfizer’s own analysis alone lists over a thousand different diagnosed adverse reactions (Click Here, Page 30-38). The failure and dangers of these genetic experiments were predictable, based on pre-2020 scientific knowledge. Yet, despite diligent efforts to warn the public, elected officials, and bureaucrats, billions of people (many repeatedly) have been subjected to these injections in what can only be described as a radical and unethical medical experiment. In many countries, including Canada, doctors who voiced caution were unlawfully persecuted—our careers, incomes, and reputations tarnished.

Moreover, similar abuses were inflicted upon doctors who reported “vaccine” injuries or attempted to treat patients suffering from COVID-19 “vaccine”-related harm. Consequently, many nurses, doctors, and health professionals who remain within the system have become victims of this unlawful injection campaign themselves. In many cases, they either cannot or will not recognize the emergence of a new cause behind the dramatic rise in deaths and diagnoses, ranging from infections and cancers to blood clots, myocarditis, miscarriages, infertility, and much more.

The New Wave of Disease

This blind spot in healthcare is causing yet another wave of harm. Individuals injured by these injections are being diagnosed using outdated criteria, and are receiving treatments that do not address the true underlying cause—the COVID injections themselves. If we are to offer hope and optimize outcomes for the billions affected, we must rectify this critical flaw in modern healthcare.

The purpose of this article is to illuminate some of the key mechanisms by which these injections are causing disease and death. Understanding the pathophysiology behind these conditions is critical for advancing life-saving care. Note that the new pathology of these injection-induced illnesses is different from prior medical understanding. Although the symptoms are similar, traditional treatments may be extremely limited without addressing the root of the issue.

---

Mechanisms of Harm

C-19 Modified mRNA Injections Contents

The injections contain a variety of components, including their declared ingredients, which are modified mRNA within pegylated lipid nanoparticles (pegLNPs). PegLNPs are tiny nanoparticles with nearly limitless tissue penetration. They deliver their genetic payloads into all tissues, including the brains, ovaries, testicles, and unborn children of any pregnant women injected.

The mRNA is modified by substituting N1-methylpseudouridine in place of uridine. This gives the RNA an unusually long lifespan of at least half a year, compared to natural mRNA, which typically lasts only a few hours. As a result, the subjects' cells continue producing the foreign coronavirus spike protein for an extended period.

This modification involving N1-methylpseudouridine also introduces errors in reading the RNA, leading to the production of a wide array of unpredictable and random proteins in addition to the spike proteins. The production of these toxic spike proteins and other protein products continues for at least six months and possibly much longer.

mRNA (left) N1-methylpseudouridine (right)

The injections also contain various undeclared contents and contaminants, including chemical contaminants and an array of plasmid DNA. The plasmid DNA includes a list of concerning genetic sequences, which are still under investigation. These include the presence of SV40 enhancer and SV40 promoter sequences—genetic engineering tools used to facilitate the incorporation of foreign DNA into the subjects' chromosomes. This raises the serious risk of permanent genetic modification in the human subjects. Research on this issue is ongoing, though we already have laboratory cell culture evidence of genetic integration of this DNA into human chromosomes.

pegLNPs is a Trogan horse to the cell membrane, full of altered mRNA

Plasmid DNA (left) Genetic sequences with SV40 enhancer and SV40 (Right)

Chemical contaminants discovered in COVID-19 injections

Nanoparticle toxicity & Polyethylene Glycol

Lipid nanoparticles have known serious toxic effects, especially if injected repeatedly, which the C-19 injections are. Polyethylene glycol triggers adverse immune responses in many people.

Lipid Nanoparticle (left) Polyethylene Glycol (right)

Toxic Spike Proteins

Coronavirus spike proteins (SP) are known toxins. The spike protein of the engineered SARS-CoV-2 virus—whether from the virus itself or produced in subjects' cells following the injections—exhibits enhanced toxicity compared to natural coronavirus spike proteins. These modifications include the incorporation of a furin cleavage site and the elimination of hemagglutinin esterase expression on the surface of the spike protein.

Blood clotting

The elimination of hemagglutinin esterase contributes to the spike protein's exceptional ability to cause blood clots at both the microscopic and macroscopic levels.

Blood Vessel Erosion

The innermost layer of cells lining blood vessels is exposed to circulating pegylated nanoparticles from the injections. These particles deliver the spike protein genetic code into the cells, causing them to produce SARS-CoV-2 spike proteins and express them on their surface. This marks these cells as foreign, triggering an immune system attack. The inner layer of cells is destroyed and sloughs off, exposing the underlying cells to the same process. In this way, the tunica intima—the innermost layer of blood vessel walls—and even deeper tissue layers of arteries and veins are damaged, eroded, and weakened. This exacerbates the enhanced blood-clotting effects of the SARS-CoV-2 spike protein, as damaged blood vessel walls are potent triggers for clot formation.

Accelerated deterioration and aging of many organs

Ongoing microvascular clotting is a contributing mechanism that accelerates organ deterioration, causing the organs of victims to age faster than normal. This can lead to a variety of clinical conditions, including accelerated microvascular dementia and kidney failure.

Reverse ORF, Spider Silk Protein, and “Calamari Clots”

One of the unusual findings in the genetic analysis of the undeclared plasmid DNA content of the C-19 mod-mRNA injections is a reverse open reading frame at the end of the plasmid DNA sequence coding for the spike protein. This causes ribosomes to also read the spike protein genetic sequence in the reverse direction, resulting in a completely different protein. The reverse sequence contains significant sections resembling the highly unusual proteins found in spider silk. This may help explain the unusual white, rubbery proteinaceous 'clots' extracted from the arteries and veins of many deceased injection victims by morticians and pathologists. The nature of these clots and the reverse translation of the spike protein genetic sequence require further study.

unusual rubbery clots found in many victims’ arteries and veins

Quasi-autoimmune pathology

Cells that produce the spike protein, as well as cells to which the spike protein adheres via ACE2 receptors, display a foreign protein on their surface. This triggers the subjects’ immune systems to attack these spike-protein-laden cells and tissues as if they were foreign, or 'non-self.' This is one of the major mechanisms of injury observed in the first year following the injections. Autopsy samples from young hearts, testicles, ovaries, kidneys, brains, placentas, and other tissues show affected organs heavily laced with spike protein and under intense autoimmune attack by the subjects' own immune systems. This resembles organ rejection seen in transplants, where the victims’ organs appear foreign to their immune system and are 'rejected.'

‘Spiked’ tissues undergoing this autoimmune attack may lead to clinical presentations in the days or months following injection, but can also contribute to progressive damage and the accelerated aging of many organs and tissues.

Quasi-autoimmune pathology

Antigenic Mimicry and Autoimmune Diseases

The spike protein also bears some resemblance to numerous natural proteins in the body, including syncytin-1, an essential protein in both female and male reproductive tissues. The immune response triggered against the spike protein can also target these natural proteins, causing another collection of autoimmune diseases and adverse effects, including miscarriages and infertility.

Ribosome Frame Shifting and More Autoimmune Disease

Due to the modified uridine in the injected mRNA, ribosome frame shifting occurs, which means that many errors are made as our cells' ribosomes read the mRNA. In addition to predominantly producing the spike protein, a large array of random proteins and protein fragments are generated. Each of these has the potential to resemble a natural protein in the body sufficiently to trigger more autoimmune diseases.

Antibody Dependent Enhancement (ADE)

The production of large amounts of spike protein within the subjects' bodies triggers a dramatic production of adaptive antibodies to the spike protein. These antibodies have various toxic effects, including the enhancement of coronavirus infections. This is one of the reasons that we observe increased rates of COVID infection, hospitalization, and death among the “vaccinated” versus the “unvaccinated.” This process is called antibody-dependent enhancement (ADE). Experimental vaccination against coronaviruses, especially against their spike protein, has been associated with a high incidence of ADE. In these experiments, like the current global experiment on humans, the antibodies produced by vaccination end up helping the virus infect the subjects rather than providing protection.

Immune System Damage, Increased Cancer and All Infections

The subjects' dramatic immune response to the spike protein produced following the injections weakens the immune system in various ways, including the suppression of CD4 and CD8 positive T cells. This damage to the subjects' immune systems is one factor accounting for the rise in cancers, particularly aggressive cancers, and a wide variety of infections among the “vaccinated.

Multiple Mechanisms to Cause Cancer

The injections have multiple mechanisms for causing cancer. These include immune system damage and chromosomal DNA damage. The insertion of foreign genetic material into the human genome has many harmful effects that are still being discovered, including the disruption of various tumor suppression genes that normally protect our DNA from damage and defend us against cancer.

Additionally, the spike protein (SP) of SARS-CoV-2 and these injections has many unique characteristics, including the capacity to migrate into our cells’ nuclei and damage the DNA, thereby interrupting tumor suppressor genes. This adds further potential mechanisms for causing cancer.

Antibody Mediated Selection: Driving the Evolution of Variants and Extending the Pandemic

Another reason many of us warned against this genetic “vaccine” program is the issue of Antibody Mediated Selection (AMS). AMS explains that although vaccination may play a role in averting a pandemic before it occurs, it is likely to prolong a pandemic and drive the evolution of one variant after another if administered during an ongoing pandemic. This serves as the foundation for a golden rule of vaccinology: we should never try to vaccinate our way out of a pandemic. Attempting to do so drives the evolution of the virus, creating one variant after another. These variants are particularly dangerous to the “vaccinated” subjects, as opposed to those with natural exposure and immunity. Natural immunity is broad and responds to many aspects of the virus, so the virus cannot simply adapt its spike protein to evade it. However, due to the injection campaigns, we have extended what would naturally have been a few months of active infections to now four years of variants, infections, and more misguided injections. This has been profitable for the vaccine industry but devastating for mankind.

Additional Mechanisms of Injury

There are additional mechanisms of injury, including prion diseases, and more research is needed regarding the injury mechanisms associated with these injections. The details of the immune system disturbances caused by these injections are extensive. This presentation serves as just a brief introduction.

Here is Pfizer's 393 page record of 4,964,106 adverse events that were reported up until June 18, 2022.

---

Where do we go from here?

COVID-19 genetic 'vaccines' offer no benefit and cause significant harm. It is long overdue to halt their manufacturing and administration. We must reinstate the scientists and doctors who have been warning about these issues, while advancing research and treatment of the resulting injuries, despite having been stripped of our positions, laboratories, and incomes. Understanding the mechanisms of injury and how to treat them, and urgently distributing this information, should be our highest priority.

New pathophysiologic mechanisms are driving dramatic increases in disease, disability, and death worldwide. The medical and scientific communities have been muzzled and co-opted, leaving healthcare practitioners 'flying blind.'

It is time to end the suppression and manipulation of medical science. We must urgently advance our understanding and treatment of the toxic effects of the COVID-19 genetic 'vaccines.'

---

44 examples of COVID 'vaccine'-induced diseases, backed by 930 scientific articles linking these conditions to the injections

The injection-induced illnesses listed here are defined according to their classifications prior to the introduction of the COVID-19 injections. While these emerging illnesses share common symptoms with conventional conditions, their underlying pathology is different. The mechanisms of injury described above must be considered, as existing medical treatments will fail to address the new root cause of these diseases.

Thanks to the community at CovidVaccineInjuries.com for compiling the studies that became the foundation of this resource. See the footnotes for the complete list of the aforementioned 930+ scientific articles. Please share this resource with patients, healthcare providers, and lawyers.

Disclaimer: This article is for educational purposes only and is not intended to be medical advice.

Table of Contents

1. Acute Hyperactive Encephalopathy

2. Acute Kidney Injury

3. Acute (Transverse) Myelitis

4. Allergic Reactions

5. Alopecia Areata

6. Anaphylaxis

7. Axillary Adenopathy

8. Bell’s Palsy

9. Bullous Drug Eruption

10. Capillary Leak Syndrome

11. Cardiac Complications

12. Central Serous Retinopathy

13. Cerebral Venous Thrombosis

14. Cutaneous Adverse Effects

15. Facial Nerve Palsy

16. Guillain-Barré Syndrome

17. Hemophagocytic Lymphohistiocytosis

18. Henoch-Schonlein Purpura

19. Immune-Mediated Disease Outbreaks

20. Immune-Mediated Hepatitis

21. Internal Bleeding

22. Intracerebral Haemorrhage

23. Lymphadenopathy

24. Multiple Sclerosis

25. Myocarditis

26. Myopericarditis

27. Nephrotic Syndrome

28. Neurological Symptoms

29. Oculomotor Paralysis

30. Pericarditis

31. Perimyocarditis

32. Petechiae

33. Prion Disease

34. Psoriasis

35. Pulmonary Embolism

36. Purpura Annularis Telangiectodes

37. Rhabdomyolysis

38. Systemic Lupus Erythematosus

39. Takotsubo Cardiomyopathy

40. Thrombocytopenia

41. Thrombosis

42. Thrombotic Thrombocytopenic Purpura

43. Vasculitis

44. Vogt-Koyanagi-Harada Syndrome

There are many more adverse event diagnosis linked to the Covid-19 genetic “Vaccines”. We will continue to expand this reference article. Meanwhile here is Pfizer's 393 page record of 4,964,106 adverse events that were reported up until June 18, 2022: Click Here

---

Acute Hyperactive Encephalopathy

Acute Hyperactive Encephalopathy refers to a sudden and intense alteration in brain function characterized by increased activity. It often manifests with symptoms such as confusion, agitation, hyperactivity, and altered consciousness. Various factors, including infections, metabolic disturbances, or drug reactions, can trigger this condition.

Acute Hyperactive Encephalopathy references¹

Acute Kidney Injury

Acute Kidney Injury (AKI) is a sudden and rapid decline in kidney function, leading to a build-up of waste products in the blood. Common causes include dehydration, infections, or medication reactions. Symptoms may include decreased urine output, swelling, and confusion.

Acute Kidney Injury references²

Acute (Transverse) Myelitis

Acute (Transverse) myelitis is a rare neurological disorder characterized by the sudden inflammation of the spinal cord, leading to motor and sensory deficits. It can result from various causes, including viral infections, autoimmune disorders, or other inflammatory conditions. Symptoms include pain, weakness, numbness, and difficulty with bladder and bowel control. Diagnosis involves clinical evaluation, imaging studies like MRI, and cerebrospinal fluid analysis.

Acute (Transverse) Myelitis references³

Acute (Transverse) Myelitis x-ray

Allergic Reactions

Allergic reactions occur when the immune system overreacts to substances (allergens) like foods, medications, or insect stings. Upon exposure, the immune system releases chemicals, such as histamine, causing symptoms like hives, itching, swelling, and in severe cases, anaphylaxis. Common allergens include nuts, pollen, and certain medications. Reactions can range from mild to life-threatening, requiring immediate medical attention. Diagnosis involves evaluating symptoms and sometimes using allergy testing.

Allergic Reactions references⁴

Allergic reaction (hives) on arm

Alopecia Areata

Alopecia areata is an autoimmune condition causing hair loss in localized patches. The immune system mistakenly attacks hair follicles, leading to hair loss. It can affect any hair-bearing area, including the scalp, eyebrows, and beard. The exact cause is unclear, but genetics and environmental factors may contribute. While the hair follicles are not permanently damaged, treatments like corticosteroids can help stimulate hair regrowth. The condition's course is unpredictable, with spontaneous regrowth or recurrent episodes possible.

Alopecia Areata references⁵

Anaphylaxis

Anaphylaxis is a severe and potentially life-threatening allergic reaction that occurs rapidly after exposure to an allergen. It involves a systemic release of chemicals, such as histamine, triggering widespread inflammation. Common allergens include certain foods, insect stings, medications, and latex. Symptoms can escalate quickly, affecting multiple organ systems and leading to difficulty breathing, a drop in blood pressure, hives, and swelling, particularly in the face and throat. Anaphylaxis requires immediate medical attention, as it can progress rapidly and lead to respiratory failure or cardiovascular collapse.

Anaphylaxis references⁶

Young woman experiencing anaphylactic shock

Axillary Adenopathy

Axillary adenopathy refers to the enlargement or swelling of lymph nodes in the armpit (axilla). Lymph nodes are part of the immune system and can become enlarged in response to various conditions. Common causes of axillary adenopathy include infections, such as localized skin infections or systemic illnesses, as well as inflammatory or neoplastic disorders. The swelling may be tender or painless and can be associated with other symptoms like fever or fatigue, depending on the underlying cause. Diagnosis involves a thorough medical history, physical examination, and sometimes imaging or biopsy.

Axillary Adenopathy references⁷

Axillary adenopathy under the right arm

Bell’s Palsy

Bell's Palsy is a sudden, temporary weakness or paralysis of the facial muscles, typically affecting one side of the face. The exact cause is often unclear, but it's thought to involve inflammation of the facial nerve, which controls facial muscles. Viral infections, particularly the herpes simplex virus, are frequently implicated. Symptoms include drooping of the mouth, difficulty closing the eye on the affected side, altered sense of taste, and facial twitching.

Bell’s Palsy references⁸

Bell’s Palsy illustration

Bullous Drug Eruption

Bullous drug eruption is a severe skin reaction marked by the development of large, fluid-filled blisters (bullae) on the skin. It is an uncommon side effect of certain medications, leading to widespread blistering and skin detachment. Lyell's syndrome, or toxic epidermal necrolysis, is an extreme form of bullous drug eruption characterized by extensive skin detachment, often requiring urgent medical intervention due to the risk of complications and mortality.

Bullous Drug Eruption references⁹

Bullous Drug Eruption (chin)

Capillary Leak Syndrome

Capillary Leak Syndrome (CLS) is a rare disorder characterized by sudden and severe leakage of fluids from blood vessels into surrounding tissues. This can lead to a rapid drop in blood volume, causing symptoms like swelling, low blood pressure, and organ dysfunction. CLS may be triggered by various factors, including infections or certain medications.

Capillary Leak Syndrome references¹⁰

Capillary leak syndrome results in dramatic swelling

Cardiac Complications

Cardiac complications refer to adverse effects impacting the heart, often resulting from conditions like heart disease, infections, or other medical issues. These may manifest as irregular heart rhythms, heart failure, or damage to the heart muscle.

Cardiac Complications references¹¹

Central Serous Retinopathy

Central Serous Retinopathy (CSR) is an eye disorder characterized by fluid accumulation beneath the retina, causing central vision distortion. This condition often affects men, primarily those in their 30s to 50s. Potential triggers include stress, corticosteroid use, and hypertension. Symptoms may include blurred or distorted vision. Although CSR often resolves on its own, persistent cases may require medical intervention, such as laser therapy.

Central Serous Retinopathy references¹²

Cerebral Venous Thrombosis

Cerebral venous thrombosis (CVT) is a rare but serious condition characterized by the formation of blood clots in the cerebral veins or sinuses, impeding blood drainage from the brain. This can lead to increased pressure within the brain, potentially causing severe headaches, visual disturbances, seizures, and neurological deficits. Risk factors include genetic predisposition, hormonal changes (such as those during pregnancy or contraceptive use), infections, and certain medical conditions. Diagnosis often involves imaging studies like MRI or CT scans.

Cerebral Venous Thrombosis references¹³

MRI of Clot in Cerebral Venous Thrombosis Stroke

Cutaneous Adverse Effects

Cutaneous adverse effects refer to skin reactions resulting from exposure to external factors, often drugs or vaccines. Lyell's syndrome, or toxic epidermal necrolysis, exemplifies a severe cutaneous adverse reaction. It is a rare, life-threatening condition characterized by widespread skin detachment and mucous membrane involvement. Such reactions can manifest as rashes, hives, or more severe conditions like Lyell's syndrome, highlighting the importance of monitoring and promptly addressing skin-related adverse events in medical contexts.

Cutaneous Adverse Effects references¹⁴

Lyell’s syndrome

Facial Nerve Palsy

Facial nerve palsy is a condition characterized by weakness or paralysis of the muscles on one side of the face, often resulting in drooping, impaired facial expressions, and difficulty closing the eye. Causes include viral infections, trauma, or tumors affecting the facial nerve. Symptoms may range from mild to severe.

Facial Nerve Palsy references¹⁵

Guillain-Barré Syndrome

A neurological disorder in which the body’s immune system mistakenly attacks part of its peripheral nervous system—the network of nerves located outside of the brain and spinal cord. Guillain-Barré Syndrome (GBS) can range from a very mild case with brief weakness to nearly devastating paralysis, leaving the person unable to breathe independently. Fortunately, most people eventually recover from even the most severe cases of GBS. After recovery, some people will continue to have some degree of weakness.

Guillain-Barré Syndrome References¹⁶

Hemophagocytic Lymphohistiocytosis

An aggressive and life-threatening syndrome of excessive immune activation. It most frequently affects infants from birth to 18 months of age, but the disease is also observed in children and adults of all ages.

Hemophagocytic Lymphohistiocytosis references¹⁷

Hemophagocytic Lymphohistiocytosis (infant)

Henoch-Schonlein Purpura

Henoch-Schonlein Purpura (HSP) is a rare autoimmune disorder primarily affecting children. It involves inflammation of small blood vessels, leading to purplish skin rash, joint pain, abdominal pain, and kidney inflammation. The exact cause is unknown, but it often follows respiratory infections. Most cases resolve on their own, but severe complications can occur.

Henoch-Schonlein Purpura references¹⁸

Immune-Mediated Disease Outbreaks

Immune-mediated disease outbreaks involve the rapid spread of illnesses triggered by the immune system's abnormal response to the body's tissues. This can result in various conditions, from autoimmune disorders to hypersensitivity reactions. These outbreaks may stem from infections, genetic factors, or environmental triggers. Examples include rheumatoid arthritis and allergic reactions.

Immune-Mediated Disease Outbreaks references¹⁹

Immune-Mediated Hepatitis

Immune-mediated hepatitis is a condition where the body's immune system mistakenly attacks the liver cells, leading to inflammation and liver dysfunction. It can result from various triggers, including infections, drugs, or autoimmune processes. Symptoms may include fatigue, jaundice, abdominal pain, and elevated liver enzymes. Diagnosis involves blood tests and imaging studies.

Immune-Mediated Hepatitis references²⁰

Location of liver

Internal Bleeding

Internal bleeding refers to the escape of blood from blood vessels inside the body. It can occur due to trauma, underlying medical conditions, or spontaneously. Symptoms may include pain, swelling, and signs of shock. Prompt medical attention is crucial to prevent complications.

Internal Bleeding references²¹

Intracerebral Haemorrhage

Intracerebral hemorrhage (ICH) is a type of stroke characterized by bleeding within the brain tissue, typically caused by the rupture of a blood vessel. This bleeding leads to the accumulation of blood and increased pressure, potentially causing neurological damage. Symptoms may include sudden and severe headaches, focal neurological deficits, and altered consciousness. Common risk factors include hypertension, cerebral amyloid angiopathy, and certain blood-thinning medications. Diagnosis involves imaging studies such as CT scans.

Intracerebral Haemorrhage references²²

Lymphadenopathy

Lymphadenopathy refers to the abnormal enlargement of lymph nodes, which are small, bean-shaped structures that play a crucial role in the immune system. This condition can be a symptom of an underlying infection, inflammation, or, in some cases, malignancy. Lymph nodes may swell as they respond to infections, such as viral or bacterial, or due to inflammatory conditions like autoimmune diseases. Common locations for lymphadenopathy include the neck, armpits, and groin. The enlargement is often accompanied by tenderness and may be associated with other symptoms like fever and fatigue. Diagnosis involves a thorough medical history, physical examination, and sometimes imaging or biopsy.

Lymphadenopathy references²³

Lymphadenopathy (female patient)

Multiple Sclerosis

Multiple Sclerosis (MS) is a chronic autoimmune disease affecting the central nervous system, causing inflammation and damage to the protective covering of nerve fibers. This disrupts communication between the brain and the body, leading to various symptoms such as fatigue, numbness, weakness, and difficulty with coordination and balance. The course of MS is unpredictable, with periods of relapse and remission.

Multiple Sclerosis references²⁴

Myocarditis

Myocarditis is an inflammatory condition affecting the myocardium, the middle layer of the heart wall. It is typically caused by viral infections, although bacteria, parasites, and certain medications can also contribute. The inflammation can weaken the heart muscle, impairing its ability to pump blood efficiently. Symptoms may include chest pain, fatigue, shortness of breath, and an irregular heartbeat. Severe cases can lead to heart failure or sudden cardiac arrest. Diagnosis involves medical history, physical exams, and imaging tests such as MRI or biopsy.

Myocarditis references²⁵

Myocarditis illustration

Myopericarditis

Myopericarditis is a condition characterized by inflammation involving both the heart muscle (myocardium) and the pericardium (the protective sac around the heart). It often results from viral infections, although bacterial or autoimmune causes can contribute. The inflammation weakens the heart muscle and may lead to chest pain, fatigue, and symptoms similar to myocarditis. Additionally, pericardial involvement can cause chest discomfort and may lead to complications like pericardial effusion. Diagnosis involves a combination of medical history, physical examination, imaging studies (such as MRI or echocardiogram), and sometimes a biopsy.

Myopericarditis references²⁶

Acute Pericarditis (inflammation of the pericardium)

Nephrotic Syndrome

Nephrotic syndrome is a kidney disorder characterized by increased protein leakage into urine, leading to swelling, low protein levels, and high cholesterol in the blood. It results from damage to the kidney's filtering units (glomeruli). Symptoms include edema, fatigue, and foamy urine.

Nephrotic Syndrome references²⁷

Nephrotic syndrome unine (left and middle) Healthy urine (right)

Neurological Symptoms

Neurological complications refer to adverse effects affecting the nervous system. These may result from various conditions, such as infections, injuries, autoimmune disorders, or metabolic abnormalities. Symptoms include altered sensation, muscle weakness, cognitive impairment, and more.

Neurological Symptoms references²⁸

Human nervous system

Oculomotor Paralysis

Oculomotor paralysis refers to the dysfunction of the oculomotor nerve, affecting eye movement control. This condition can lead to impaired coordination, double vision, and difficulty focusing.

Oculomotor Paralysis references²⁹

Pericarditis

Pericarditis is inflammation of the pericardium, the sac around the heart. It causes chest pain, often sharp and worsened by breathing. Myopericarditis involves inflammation of both the pericardium and the heart muscle (myocardium), while myocarditis solely targets the myocardium. Pericarditis and myopericarditis typically result from infections or autoimmune disorders, while myocarditis often stems from viral infections. The key difference lies in the extent of inflammation, with pericarditis affecting the pericardium and myopericarditis involving both the pericardium and myocardium. Symptoms overlap, but myopericarditis might present with additional cardiac manifestations. Diagnosis involves imaging and blood tests.

Pericarditis references³⁰

Comparison to normal heart

Perimyocarditis

Perimyocarditis refers to inflammation involving both the outer layer of the heart (pericardium) and the adjacent heart muscle (myocardium). It shares characteristics with pericarditis and myocarditis. Commonly caused by viral infections or autoimmune processes, perimyocarditis manifests as chest pain, fatigue, and potential cardiac complications. Diagnosis involves clinical assessment, imaging (such as MRI), and laboratory tests.

Perimyocarditis references³¹

Illustration depicting pericardium and myocardium

Petechiae

Petechiae are small, red or purple spots on the skin caused by bleeding under the skin. Resulting from broken capillaries, they appear as pinpoint-sized dots and may signal various medical conditions like platelet disorders, infections, or trauma. Petechiae can also be associated with severe conditions like meningitis or certain bleeding disorders.

Petechiae references³²

Petechiae (back of mouth)

Prion Disease

Prion diseases are a group of rare and fatal neurodegenerative disorders caused by abnormal proteins called prions. These misfolded proteins accumulate in the brain, leading to neuronal damage. Prion diseases, such as Creutzfeldt-Jakob disease, result in rapidly progressive cognitive and motor dysfunction. The abnormal prions induce the misfolding of normal proteins, creating a self-perpetuating cycle of protein aggregation and neurotoxicity.

Prion Disease references³³

Creutzfelft-Jakob disease

Psoriasis

Psoriasis is a chronic autoimmune skin disorder characterized by red, inflamed patches with silvery scales. The immune system mistakenly accelerates skin cell turnover, causing excessive cell buildup on the surface. This results in the formation of raised, scaly plaques.

Psoriasis references³⁴

Psoriasis (scalp)

Pulmonary Embolism

Pulmonary embolism (PE) is a serious medical condition where a blood clot, typically originating in the legs, travels to the lungs and blocks a pulmonary artery. This obstruction can lead to restricted blood flow, causing symptoms such as shortness of breath, chest pain, and cough. Risk factors include deep vein thrombosis, surgery, prolonged immobility, and certain medical conditions. Prompt diagnosis through imaging, such as CT pulmonary angiography, is crucial.

Pulmonary Embolism references³⁵

Pulmonary Embolism

Purpura Annularis Telangiectodes

Purpura annularis telangiectodes (PAT) is a rare skin disorder characterized by reddish-purple, ring-shaped skin lesions with central clearing and dilated blood vessels (telangiectasia). It falls under the category of pigmented purpuric dermatoses.

Purpura Annularis Telangiectodes references³⁶

Purpura Annularis Telangiectodes

Rhabdomyolysis

Rhabdomyolysis is a serious condition characterized by the breakdown of muscle tissue, releasing a protein called myoglobin into the bloodstream. This can lead to kidney damage and other complications. Causes include trauma, muscle injury, medications, or metabolic disorders. Symptoms may include muscle pain, weakness, and dark urine. Diagnosis involves blood tests and urine analysis.

Rhabdomyolysis references³⁷

Rhabdomyolysis - toxic muscular content leaks into the bloodstream, resulting in coke-coloured urine

Systemic Lupus Erythematosus

Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease where the immune system mistakenly attacks healthy tissues throughout the body. Symptoms vary widely, ranging from joint pain and skin rashes to more severe complications affecting organs like the kidneys and heart.

Systemic Lupus Erythematosus references³⁸

Systemic Lupus Erythematosus

Takotsubo Cardiomyopathy

Takotsubo cardiomyopathy, often called "broken heart syndrome," is a temporary heart condition characterized by sudden and intense chest pain, shortness of breath, and changes in heart function. It can be triggered by severe emotional or physical stress, leading to a unique ballooning of the heart's left ventricle. Despite its initial severity, Takotsubo cardiomyopathy is typically reversible, and the heart often returns to normal function.

Takotsubo Cardiomyopathy references³⁹

Thrombocytopenia

Thrombocytopenia is a medical condition characterized by a low platelet count in the blood. Platelets are crucial for blood clotting, and a decreased count can lead to increased bleeding and difficulty forming clots. Various factors contribute to thrombocytopenia, including immune system disorders, medications, infections, or bone marrow disorders. Symptoms may include easy bruising, petechiae (small red or purple spots on the skin), and prolonged bleeding from minor injuries. Diagnosis involves blood tests to measure platelet levels and assess their functionality.

Thrombocytopenia references⁴⁰

Thrombocytopenia illustration

Thrombosis

Thrombosis is a medical condition characterized by the formation of blood clots within blood vessels, obstructing normal blood flow. These clots, known as thrombi, can develop in arteries or veins, leading to serious complications. Arterial thrombosis may result in conditions such as stroke or heart attack, while venous thrombosis can cause deep vein thrombosis (DVT) or pulmonary embolism. Various factors contribute to thrombosis, including immobility, surgery, genetic predisposition, or underlying medical conditions. Symptoms depend on the location and extent of the clot but may include pain, swelling, and redness. Diagnosis involves imaging tests like ultrasound or CT scans.

Thrombosis references⁴¹

Deep Vein Thrombosis

Thrombotic Thrombocytopenic Purpura

Thrombotic Thrombocytopenic Purpura (TTP) is a rare blood disorder characterized by widespread clot formation in small blood vessels, leading to low platelet count and potential organ damage. Often caused by a deficiency in ADAMTS13 enzyme, vital for preventing excessive clotting, TTP results in microvascular thrombosis. Symptoms include purpura, neurological issues, fever, and kidney dysfunction.

Thrombotic Thrombocytopenic Purpura references⁴²

Thrombotic Thrombocytopenic Purpura (arm)

Vasculitis

Vasculitis is a group of inflammatory disorders characterized by the inflammation of blood vessels. The immune system mistakenly attacks blood vessel walls, leading to swelling, narrowing, and possible blockages. Vasculitis can affect arteries, veins, and capillaries throughout the body, impacting various organs and tissues. The exact cause is often unknown, but it may result from infections, autoimmune diseases, or certain medications. Symptoms vary based on the affected vessels and organs but may include fatigue, fever, weight loss, and organ-specific issues. Diagnosis involves clinical evaluation, blood tests, imaging studies, and sometimes a biopsy.

Vasculitis references⁴³

Vasculitis on inside of calves

Vogt-Koyanagi-Harada Syndrome

Vogt-Koyanagi-Harada (VKH) Syndrome is a rare autoimmune disorder affecting melanin-containing tissues, particularly the eyes, ears, skin, and meninges. Characterized by inflammation, it often results in bilateral uveitis, hearing loss, and skin depigmentation. The immune response targets melanocytes, leading to a spectrum of symptoms.

Vogt-Koyanagi-Harada Syndrome references⁴⁴

Rapid loss in vision from Vogt-Koyanagi-Harada syndrome

---

Closing Statement

We hope you find this comprehensive resource useful in your applied understanding of diseases potentially caused by the COVID-19 mRNA genetic therapy injections. If you would like to support this work, please subscribe to my Substack and share my material.

---

References

Mechanism of Harm

1. BNT162b2 - 5.3.6 Cumulative Analysis of Post-authorization Adverse Event Reports

2. Effectiveness of the Coronavirus Disease 2019 Bivalent Vaccine

3. The True “Efficacy” of COVID-19 Vaccines - International Covid Summit Presentation to the Parliament of Romania

4. How SARS CoV2 and the Genetic Jabs Cause Blood Clots

5. Sialylated Glycan Bindings from SARS-CoV-2 Spike Protein to Blood and Endothelial Cells Govern the Severe Morbidities of COVID-19

6. Furin Cleavage Site in the SARS-CoV-2 Coronavirus Glycoprotein

7. Anti-PEG Antibodies: Properties, Formation, Testing, and Role in Adverse Immune Reactions to PEGylated Nano-biopharmaceuticals

8. Daily Clout - Report 74: Lipid Nanoparticles Corrupt Nature

9. Hypersensitivity to Polyethylene Glycol in Adults and Children: An Emerging Challenge

10. SARS-CoV2 Spike Protein Elicits Cell Signaling in Human Host Cells: Implications for Possible Consequences of COVID-19 Vaccines

11. SARS-CoV-2 Spike Protein Impairs Endothelial Function via Downregulation of ACE 2

12. There’s DNA in the RNA Shots. Lots!

13. COVID-19 mRNA Vaccines Contain Excessive Quantities of Bacterial DNA: Evidence and Implications

14. World Council For Health: Urgent Panel of Global Experts Confirm Dangerous Criminal Undeclared DNA in Pfizer and Moderna Covid-19 Vaccines

15. Complete C-19 Genetic Vaccines Science Update

16. Jessica Rose, Substack - What a Tangled Web We May Have Weaved

17. Embalmers Are Finding Unusual Blood Clots

18. Autopsies

19. Microscopic Evidence of Spike Protein Studded Tissues Under Autoimmune Attack Following COVID-19 Genetic Vaccines

20. A Case Report: Multifocal Necrotizing Encephalitis and Myocarditis After BNT162b2 mRNA Vaccination Against COVID-19

21. Dropping Sperm Counts and Poisonous Ejaculate - Evidence from Autopsies, Pfizer Documents, and Global Statistics

22. Striking Similarity Between Human Syncytins and the SARS-CoV-2 Spike Protein

23. Ribosomal Frameshifting

24. N1-Methylpseudouridylation of mRNA Causes +1 Ribosomal Frameshifting

25. The True “Efficacy” of COVID-19 Vaccines

26. Antibody Dependent Enhancement - Dr. Trozzi

27. Immunization with SARS Coronavirus Vaccines Leads to Pulmonary Immunopathology on Challenge with the SARS Virus

28. Why So Many Vaccinated People Are Getting Sick: Antibody Dependent Enhancement (ADE)

29. How the COVID Vaccines Cripple the Immune System | Series

30. How COVID Jabs Harm the Immune System & Help New Variants Evolve

31. Dr. McCullough Warns: Getting Jabbed Multiple Times with mRNA COVID Vaccines Could Promote “Turbo Cancer”

32. Dr. Ryan Cole: How the COVID Vaccines Cause Cancer

33. Global Cancer Rates Exploding Post Vaccines & Being Covered Up

34. Antibody Mediated Selection

35. Neurotoxic Amyloidogenic Peptides in the Proteome of SARS-CoV-2: Potential Implications for Neurological Symptoms in COVID-19

36. SARS-CoV-2 Spike Protein in the Pathogenesis of Prion-like Diseases

37. mRNA Vaccine Toxicity - Doctors for Covid Ethics

38. Pfizer’s own documents: Cumulative and Interval Summary Tabulation of Serious and Non-Serious Adverse Reactions from Post-Marketing Data Sources (21 June, 2022)

1. Acute Hyperactive Encephalopathy references

1. Acute Hyperactive Encephalopathy Following COVID-19 Vaccination with Dramatic Response to Methylprednisolone: A Case Report

2. Post-vaccinal Encephalitis after ChAdOx1 nCov-19

3. Acute Disseminated Encephalomyelitis Following Vaccination Against SARS-CoV-2

4. Acute Hyperactive Encephalopathy Following COVID-19 Vaccination with Dramatic Response to Methylprednisolone: Case Report

2. Acute Kidney Injury references

1. Minimal Change Disease with Severe Acute Kidney Injury after Oxford-AstraZeneca COVID-19 Vaccine: Case Report

2. Acute Kidney Injury with Macroscopic Hematuria and IgA Nephropathy after COVID-19 Vaccination

3. Minimal Change Disease and Acute Kidney Injury after Pfizer-BioNTech COVID-19 Vaccine

3. Acute (Transverse) Myelitis references

1. Acute Myelitis and ChAdOx1 nCoV-19 Vaccine: Coincidental or Causal Association

2. Acute Transverse Myelitis (ATM): Clinical Review of 43 Patients with COVID-19-Associated ATM and 3 Serious Adverse Events of Post-Vaccination ATM with ChAdOx1 nCoV-19 Vaccine (AZD1222)

3. Transverse Myelitis Induced by SARS-CoV-2 Vaccination

4. Acute Transverse Myelitis (ATM): Clinical Review of 43 Patients with COVID-19-Associated ATM and 3 Serious Adverse Events of Post-Vaccination ATM with ChAdOx1 nCoV-19 (AZD1222) Vaccine

5. Acute Transverse Myelitis After COVID-19 Vaccination

6. Extensive Longitudinal Transverse Myelitis After ChAdOx1 nCOV-19 Vaccine: Case Report

7. Acute Transverse Myelitis After SARS-CoV-2 Vaccination: Case Report and Review of the Literature

8. Acute Transverse Myelitis Following Inactivated COVID-19 Vaccine

9. Acute Transverse Myelitis After COVID-19 Vaccination

10. A Case of Longitudinally Extensive Transverse Myelitis Following Covid-19 Vaccination

11. Post COVID-19 Transverse Myelitis; A Case Report with Review of the Literature

12. Acute Bilateral Bilateral Optic Neuritis/Chiasm with Longitudinal Extensive Transverse Myelitis in Long-standing Stable Multiple Sclerosis After Vector-Based Vaccination Against SARS-CoV-19

13. Extensive Longitudinal Transverse Myelitis Following AstraZeneca COVID-19 Vaccination

14. Extensive Longitudinal Transverse Myelitis Following AstraZeneca COVID-19 Vaccination

15. Longitudinally Extensive Cervical Myelitis After Vaccination with Inactivated Virus Based COVID-19 Vaccine

4. Allergic Reactions references

1. An Academic Hospital Experience Assessing the Risk of COVID-19 mRNA Vaccine Using Patient’s Allergy History

2. Allergic Reactions, Including Anaphylaxis, After Receiving the First Dose of the Pfizer-BioNTech COVID-19 Vaccine

3. Allergic Reactions to the First COVID-19 Vaccine: A Potential Role of Polyethylene Glycol

4. Pfizer Vaccine Raises Allergy Concerns

5. Allergic Reactions, Including Anaphylaxis, After Receiving the First Dose of Pfizer-BioNTech COVID-19 Vaccine – United States, December 14-23, 2020

6. Allergic Reactions, Including Anaphylaxis, After Receiving First Dose of Modern COVID-19 Vaccine – United States, December 21, 2020-January 10, 2021

7. Severe Allergic Reactions After COVID-19 Vaccination with the Pfizer/BioNTech Vaccine in Great Britain and the USA: Position Statement of the German Allergy Societies

8. Allergic Reactions and Anaphylaxis to LNP-Based COVID-19 Vaccines

9. Allergenic Components of the mRNA-1273 Vaccine for COVID-19: Possible Involvement of Polyethylene Glycol and IgG-Mediated Complement Activation

10. Acute Allergic Reactions to COVID-19 mRNA Vaccines

11. Polyethylene Glycol Allergy of the SARS CoV2 Vaccine Recipient: Case Report of a Young Adult Recipient and Management of Future Exposure to SARS-CoV2

12. Allergic Reactions and Adverse Events Associated with Administration of mRNA-Based Vaccines. A Health System Experience

13. Allergic Reactions to COVID-19 Vaccines: Statement of the Belgian Society of Allergy and Clinical Immunology (BelSACI)

14. Allergic Reactions After COVID-19 Vaccination: Putting the Risk in Perspective

15. Risk of Severe Allergic Reactions to COVID-19 Vaccines Among Patients with Allergic Skin Disease: Practical Recommendations. An ETFAD Position Statement with External Experts

16. Association of Self-Reported History of High-Risk Allergy with Allergy Symptoms After COVID-19 Vaccination

17. The Risk of Allergic Reaction to SARS-CoV-2 Vaccines and Recommended Evaluation and Management: A Systematic Review, Meta-Analysis, GRADE Assessment, and International Consensus Approach

18. Practical Handling of Allergic Reactions to COVID-19 Vaccines: A Position Paper from German and Austrian Allergy Societies AeDA, DGAKI, GPA and OGAI

19. Severe Allergic Reactions After COVID-19 Vaccination with the Pfizer/BioNTech Vaccine in Great Britain and USA: Position Statement of the German Allergy Societies

20. Assessment of Allergic and Anaphylactic Reactions to mRNA COVID-19 Vaccines with Confirmatory Testing in a US Regional Health System

21. A Case Series of Skin Reactions to COVID-19 Vaccine in the Department of Dermatology at Loma Linda University

22. Skin Reactions Reported After Moderna and Pfizer’s COVID-19 Vaccination: A Study Based on a Registry of 414 Cases

23. Skin Reactions After Vaccination Against SARS-CoV-2: A Nationwide Spanish Cross-Sectional Study of 405 Cases

24. Coagulopathies After SARS-CoV-2 Vaccination May Derive from a Combined Effect of SARS-CoV-2 Spike Protein and Adenovirus Vector-Activated Signaling Pathways

25. Diffuse Prothrombotic Syndrome After Administration of ChAdOx1 nCoV-19 Vaccine: Case Report

26. Concerning the Unexpected Prothrombotic State Following Some Coronavirus Disease 2019 Vaccines (Calcaterra, G., et al.)

27. Post-Vaccination Multisystem Inflammatory Syndrome in Adults Without Evidence of Prior SARS-CoV-2 Infection

28. Autoantibody Release in Children After Coronavirus mRNA Vaccination: A Risk Factor of Multisystem Inflammatory Syndrome? (Buchhorn, R., et al.)

5. Alopecia Areata references

1. Recurrence of alopecia areata after COVID-19 vaccination: a report of three cases in Italy

6. Anaphylaxis references

1. COVID-19 Vaccine-Associated Anaphylaxis: A Statement from the Anaphylaxis Committee of the World Allergy Organization

2. Allergic Reactions, Including Anaphylaxis, After Receiving the First Dose of the Pfizer-BioNTech COVID-19 Vaccine

3. Allergic Reactions, Including Anaphylaxis, After Receiving the First Dose of Pfizer-BioNTech COVID-19 Vaccine – United States, December 14-23, 2020

4. Allergic Reactions, Including Anaphylaxis, After Receiving First Dose of Modern COVID-19 Vaccine – United States, December 21, 2020-January 10, 2021

5. Reports of Anaphylaxis After Coronavirus Disease Vaccination 2019, South Korea, February 26-April 30, 2021

6. Reports of Anaphylaxis After Receiving COVID-19 mRNA Vaccines in the U.S.-Dec 14, 2020-Jan 18, 2021

7. Immunization Practices and Risk of Anaphylaxis: A Current, Comprehensive Update of COVID-19 Vaccination Data

8. Relationship Between Pre-existing Allergies and Anaphylactic Reactions Following Administration of COVID-19 mRNA Vaccine

9. Anaphylaxis Associated with COVID-19 mRNA Vaccines: Approach to Allergy Research

10. Allergic Reactions and Anaphylaxis to LNP-Based COVID-19 Vaccines

11. Cumulative Adverse Event Report of Anaphylaxis Following Injections of COVID-19 mRNA Vaccine (Pfizer-BioNTech) in Japan: The First Month Report

12. COVID-19 Vaccines Increase the Risk of Anaphylaxis

13. Biphasic Anaphylaxis After Exposure to the First Dose of the Pfizer-BioNTech COVID-19 mRNA Vaccine COVID-19

14. Polyethylene Glycol (PEG) Is a Cause of Anaphylaxis to Pfizer/BioNTech mRNA COVID-19 Vaccine

15. Elevated Rates of Anaphylaxis After Vaccination With Pfizer BNT162b2 mRNA Vaccine Against COVID-19 in Japanese Healthcare Workers; A Secondary Analysis of Initial Post-Approval Safety Data

16. IgE-Mediated Allergy to Polyethylene Glycol (PEG) as a Cause of Anaphylaxis to COVID-19 mRNA Vaccines

17. Anaphylactic Reactions to COVID-19 mRNA Vaccines: A Call for Further Studies

18. Anaphylaxis Following COVID-19 Vaccine in a Patient With Cholinergic Urticaria

19. Anaphylaxis Induced by CoronaVac COVID-19 Vaccine: Clinical Features and Results of Revaccination

20. Anaphylaxis After Modern COVID-19 Vaccine

21. Sex Differences in the Incidence of Anaphylaxis to LNP-mRNA Vaccines COVID-19

22. Allergic Reactions, Including Anaphylaxis, After Receiving the First Dose of Pfizer-BioNTech COVID-19 Vaccine – United States, December 14 to 23, 2020

23. Allergic Reactions, Including Anaphylaxis, After Receiving the First Dose of Modern COVID-19 Vaccine – United States, December 21, 2020 to January 10, 2021

24. Prolonged Anaphylaxis to Pfizer 2019 Coronavirus Disease Vaccine: A Case Report and Mechanism of Action

25. Anaphylaxis Reactions to Pfizer BNT162b2 Vaccine: Report of 3 Cases of Anaphylaxis Following Vaccination with Pfizer BNT162b2

26. Biphasic Anaphylaxis After First Dose of 2019 Messenger RNA Coronavirus Disease Vaccine with Positive Polysorbate 80 Skin Test Result

27. Biphasic Anaphylaxis After Exposure to the First Dose of Pfizer-BioNTech COVID-19 mRNA Vaccine COVID-19

28. Cumulative Adverse Event Reporting of Anaphylaxis After mRNA COVID-19 Vaccine (Pfizer-BioNTech) Injections in Japan: The First-Month Report

29. Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine – United States, December 14-23, 2020

7. Axillary Adenopathy references

1. COVID-19 Vaccine-Induced Axillary and Pectoral Lymphadenopathy in PET

2. Evolution of Bilateral Hypermetabolic Axillary Lymphadenopathy on FDG PET/CT After 2-Dose COVID-19 Vaccination

3. COVID-19 Vaccine-Related Axillary Lymphadenopathy in Breast Cancer Patients: Case Series With Literature Review

4. Subclinical Axillary Lymphadenopathy Associated With COVID-19 Vaccination on Screening Mammography

5. Axillary Adenopathy Associated With COVID-19 Vaccination: Imaging Findings and Follow-Up Recommendations in 23 Women

6. Unilateral Axillary Adenopathy in the Setting of COVID-19 Vaccination: Follow-Up

7. COVID-19 Vaccine-Related Axillary and Cervical Lymphadenopathy in Patients With Current or Previous Breast Cancer and Other Malignancies: Cross-Sectional Imaging Findings on MRI, CT, and PET-CT

8. Incidence of Axillary Adenopathy on Breast Imaging After Vaccination with COVID-19

9. Unilateral Axillary Lymphadenopathy Related to COVID-19 Vaccine: Pattern on Screening Breast MRI Allowing Benign Evaluation

10. Axillary Lymphadenopathy in Patients With Recent COVID-19 Vaccination: A New Diagnostic Dilemma

11. COVID-19 Vaccine-Induced Unilateral Axillary Adenopathy: Follow-Up Evaluation in the USA

12. Adenopathy After COVID-19 Vaccination

8. Bell’s Palsy references

1. Bell’s Palsy and SARS-CoV-2 Vaccines: An Unfolding Story

2. Bell’s Palsy After the Second Dose of the Pfizer COVID-19 Vaccine in a Patient With a History of Recurrent Bell’s Palsy

3. Bell’s Palsy After COVID-19 Vaccination: Case Report

4. The Association Between COVID-19 Vaccination and Bell’s Palsy

5. Bell’s Palsy After COVID-19 Vaccination

6. Bell’s Palsy After 24 Hours of mRNA-1273 SARS-CoV-2 mRNA-1273 Vaccine

7. Bell’s Palsy After Ad26.COV2.S COVID-19 Vaccination

8. Bell’s Palsy After COVID-19 Vaccination: Case Report

9. Acute Facial Paralysis as a Possible Complication of SARS-CoV-2 Vaccination

10. Bell’s Palsy After COVID-19 Vaccination With High Antibody Response in CSF

11. Bell’s Palsy After a Single Dose of Vaccine mRNA SARS-CoV-2: Case Report

12. Adverse Event Reporting and Risk of Bell’s Palsy After COVID-19 Vaccination

13. Bilateral Facial Nerve Palsy and COVID-19 Vaccination: Causality or Coincidence

14. Left Bell’s Palsy After the First Dose of mRNA-1273 SARS-CoV-2 Vaccine: Case Report

15. Bell’s Palsy After Inactivated Vaccination With COVID-19 in a Patient With a History of Recurrent Bell’s Palsy: Case Report

16. Bell’s Palsy After Vaccination With mRNA (BNT162b2) and Inactivated (CoronaVac) SARS-CoV-2 Vaccines: A Case Series and a Nested Case-Control Study

17. A Case of Acute Demyelinating Polyradiculoneuropathy With Bilateral Facial Palsy After ChAdOx1 nCoV-19 Vaccine

18. Type I Interferons as a Potential Mechanism Linking COVID-19 mRNA Vaccines With Bell’s Palsy

9. Bullous Drug Eruption references

1. Bullous Drug Eruption After the Second Dose of COVID-19 mRNA-1273 (Moderna) Vaccine: Case Report

2. Widespread Fixed Bullous Drug Eruption After Vaccination With ChAdOx1 nCoV-19

10. Capillary Leak Syndrome references

1. Fatal Systemic Capillary Leak Syndrome After SARS-CoV-2 Vaccination in a Patient With Multiple Myeloma

2. Systemic Capillary Extravasation Syndrome Following Vaccination with ChAdOx1 nCoV-19 (Oxford-AstraZeneca)

11. Cardiac Complications references

1. Transient Cardiac Injury in Adolescents Receiving the BNT162b2 mRNA COVID-19 Vaccine

2. Cardiac Complications Following mRNA COVID-19 Vaccines: A Systematic Review of Case Reports and Case Series

3. A Review of COVID-19 Vaccination and the Reported Cardiac Manifestations

4. Temporal Relationship Between the Second Dose of BNT162b2 mRNA Covid-19 Vaccine and Cardiac Involvement in a Patient With Previous SARS-COV-2 Infection

5. Autopsy Findings and Causality Relationship Between Death and COVID-19 Vaccination: A Systematic Review

6. Post-Mortem Investigation of Deaths After Vaccination with COVID-19 Vaccines

7. A Look at the Role of Postmortem Immunohistochemistry in Understanding the Inflammatory Pathophysiology of COVID-19 Disease and Vaccine-Related Thrombotic Adverse Events: A Narrative Review

8. COVID-19 Vaccine and Death: Causality Algorithm According to the WHO Eligibility Diagnosis

9. Myocarditis and Other Cardiovascular Complications of COVID-19 mRNA-based COVID-19 Vaccines

10. Cardiovascular Magnetic Resonance Imaging Findings in Young Adult Patients with Acute Myocarditis after COVID-19 mRNA Vaccination: A Case Series

11. Be Alert to the Risk of Adverse Cardiovascular Events after COVID-19 Vaccination

12. Myocarditis and Other Cardiovascular Complications of mRNA-based COVID-19 Vaccines

12. Central Serous Retinopathy references

1. Acute-onset central serous retinopathy after immunization with COVID-19 mRNA vaccine

13. Cerebral Venous Thrombosis References

1. Cerebral Venous Sinus Thrombosis in the U.S. Population After SARS-CoV-2 Vaccination with Adenovirus and After COVID-19

2. Cerebral Venous Sinus Thrombosis Negative for Anti-PF4 Antibody Without Thrombocytopenia After Immunization with COVID-19 Vaccine in a Non-Comorbid Elderly Indian Male Treated with Conventional Heparin-Warfarin Based Anticoagulation

3. Cerebral Venous Thrombosis After BNT162b2 mRNA SARS-CoV-2 Vaccine

4. Cerebral Venous Sinus Thrombosis After Vaccination: The United Kingdom Experience

5. US Case Reports of Cerebral Venous Sinus Thrombosis with Thrombocytopenia After Vaccination with Ad26.COV2.S (against COVID-19), March 2 to April 21, 2020

6. Management of Cerebral and Splanchnic Vein Thrombosis Associated with Thrombocytopenia in Subjects Previously Vaccinated with Vaxzevria (AstraZeneca): Position Statement of the Italian Society for the Study of Hemostasis and Thrombosis (SISET)

7. Vaccine-Induced Immune Thrombotic Thrombocytopenia and Cerebral Venous Sinus Thrombosis After Vaccination with COVID-19: A Systematic Review

8. Early Results of Bivalirudin Treatment for Thrombotic Thrombocytopenia and Cerebral Venous Sinus Thrombosis After Vaccination with COV2.S

9. A Rare Case of a Middle-Aged Asian Male with Cerebral Venous Thrombosis After AstraZeneca COVID-19 Vaccination

10. Cerebral Venous Sinus Thrombosis and Thrombocytopenia After COVID-19 Vaccination: Report of Two Cases in the United Kingdom

11. Diagnostic-Therapeutic Recommendations of the Ad-Hoc FACME Expert Working Group on the Management of Cerebral Venous Thrombosis Related to COVID-19 Vaccination

12. COVID-19 Vaccination: Information on the Occurrence of Arterial and Venous Thrombosis Using Data from VigiBase

13. Cerebral Venous Thrombosis Associated with the COVID-19 Vaccine in Germany

14. Cerebral Venous Thrombosis Following BNT162b2 mRNA Vaccination of BNT162b2 Against SARS-CoV-2: A Black Swan Event

15. The Importance of Recognizing Cerebral Venous Thrombosis Following Anti-COVID-19 Vaccination

16. Cerebral Venous Sinus Thrombosis Negative for Anti-PF4 Antibody Without Thrombocytopenia After Immunization with COVID-19 Vaccine in an Elderly, Non-Comorbid Indian Male Treated with Conventional Heparin-Warfarin-Based Anticoagulation

17. Vaccine-Induced Immune Thrombotic Thrombocytopenia and Cerebral Venous Sinus Thrombosis After COVID-19 Vaccination: A Systematic Review

18. A Rare Case of Cerebral Venous Thrombosis and Disseminated Intravascular Coagulation Temporally Associated with Administration of COVID-19 Vaccine

19. Acute Cerebral Venous Thrombosis and Pulmonary Artery Embolism Associated with the COVID-19 Vaccine

20. Cerebral Venous Sinus Thrombosis and Vaccine-Induced Thrombocytopenia: A Missed Opportunity for a Rapid Return on Experience

21. Diagnosis and Treatment of Cerebral Venous Sinus Thrombosis with Vaccine-Induced Immune Thrombotic Thrombocytopenia

22. Venous Sinus Thrombosis After Vaccination with ChAdOx1 nCov-19

23. Cerebral Venous Thrombosis Following Vaccination Against SARS-CoV-2: An Analysis of Cases Reported to the European Medicines Agency

24. Arterial Events, Venous Thromboembolism, Thrombocytopenia, and Bleeding After Vaccination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway: Population-Based Cohort Study

25. Cerebral Venous Thrombosis Associated with COVID-19 Vaccine in Germany

26. Malignant Cerebral Infarction After Vaccination with ChAdOx1 nCov-19: A Catastrophic Variant of Vaccine-Induced Immune-Mediated Thrombotic Thrombocytopenia

27. Cerebral Venous Sinus Thrombosis Associated with Thrombocytopenia After COVID-19 Vaccination

28. Central Venous Sinus Thrombosis with Subarachnoid Hemorrhage After COVID-19 mRNA Vaccination: Are These Reports Merely Coincidental?

29. Cerebral Venous Sinus Thrombosis Negative for Anti-PF4 Antibody Without Thrombocytopenia After Immunization with COVID-19 Vaccine in a Non-Comorbid Elderly Indian Male Treated with Conventional Heparin-Warfarin-Based Anticoagulation

30. Cerebral Venous Sinus Thrombosis 2 Weeks After First Dose of SARS-CoV-2 mRNA Vaccine

31. Deep Venous Thrombosis (DVT) Occurring Shortly After the Second Dose of SARS-CoV-2 mRNA Vaccine

32. Vaccine-Induced Immune Thrombotic Thrombocytopenia Causing a Severe Form of Cerebral Venous Thrombosis with High Mortality Rate: A Case Series

33. Procoagulant Microparticles: A Possible Link Between Vaccine-Induced Immune Thrombocytopenia (VITT) and Cerebral Sinus Venous Thrombosis

34. Acute Cerebral Venous Thrombosis and Pulmonary Artery Embolism Associated with the COVID-19 Vaccine

35. Cerebral Venous Thrombosis Following COVID-19 Vaccination

36. Adverse Effects Reported After COVID-19 Vaccination in a Tertiary Care Hospital, Centered on Cerebral Venous Sinus Thrombosis (CVST)

37. Cerebral Venous Thrombosis Associated with COVID-19 Vaccine in Germany

38. Cerebral Venous Sinus Thrombosis After COVID-19 Vaccination: Neurological and Radiological Management

39. Cerebral Venous Thrombosis and Thrombocytopenia After COVID-19 Vaccination

40. Cerebral Venous Sinus Thrombosis and Thrombocytopenia After COVID-19 Vaccination: Report of Two Cases in the United Kingdom

41. Cerebral Venous Thrombosis Induced by SARS-CoV-2 Vaccine

42. Cerebral Venous Sinus Thrombosis Associated with Vaccine-Induced Thrombotic Thrombocytopenia

43. Cerebral Venous Thrombosis After the BNT162b2 mRNA SARS-CoV-2 Vaccine

44. Cerebral Venous Thrombosis After COVID-19 Vaccination

45. Lethal Cerebral Venous Sinus Thrombosis After COVID-19 Vaccination

46. Cerebral Venous Sinus Thrombosis in the U.S. Population After SARS-CoV-2 Vaccination with Adenovirus and After COVID-19

47. Cerebral Venous Thrombosis After COVID-19 Vaccination: Is the Risk of Thrombosis Increased by Intravascular Administration of the Vaccine

48. Central Venous Sinus Thrombosis with Subarachnoid Hemorrhage After COVID-19 mRNA Vaccination: Are These Reports Merely Coincidental?

49. Cerebral Venous Sinus Thrombosis After ChAdOx1 nCov-19 Vaccination with a Misleading First Brain MRI

50. Early Results of Bivalirudin Treatment for Thrombotic Thrombocytopenia and Cerebral Venous Sinus Thrombosis After Vaccination with Ad26.COV2.S

51. Cerebral Venous Sinus Thrombosis Associated with Post-Vaccination Thrombocytopenia by COVID-19

52. Cerebral Venous Sinus Thrombosis 2 Weeks After the First Dose of SARS-CoV-2 mRNA Vaccine

53. Adverse Effects Reported After COVID-19 Vaccination in a Tertiary Care Hospital, Focus on Cerebral Venous Sinus Thrombosis (CVST)

54. Cerebral Venous Sinus Thrombosis Following Vaccination Against SARS-CoV-2: An Analysis of Cases Reported to the European Medicines Agency

55. A Rare Case of a Middle-Age Asian Male with Cerebral Venous Thrombosis After COVID-19 AstraZeneca Vaccination

56. Massive Cerebral Venous Thrombosis and Venous Basin Infarction as Late Complications of COVID-19: A Case Report

57. Massive Cerebral Venous Thrombosis Due to Vaccine-Induced Immune Thrombotic Thrombocytopenia

58. Cerebral Venous Thrombosis Developing After Vaccination, COVID-19: VITT, VATT, TTS and More

59. Cerebral Venous Thrombosis and Myeloproliferative Neoplasms: A Three-Center Study of 74 Consecutive Cases

60. Vaccine-Induced Cerebral Venous Thrombosis and Thrombocytopenia, Oxford-AstraZeneca COVID-19: A Missed Opportunity for Rapid Return on Experience

61. Case Report: Take a Second Look - Cerebral Venous Thrombosis Related to Covid-19 Vaccination and Thrombotic Thrombocytopenia Syndrome

14. Cutaneous Adverse Effects references

1. Cutaneous Adverse Effects of Available COVID-19 Vaccines

2. Rare Cutaneous Adverse Effects of COVID-19 Vaccines: A Case Series and Review of the Literature

3. Cutaneous Adverse Reactions of 35,229 Doses of COVID-19 Sinovac and AstraZeneca Vaccine COVID-19: A Prospective Cohort Study in Health Care Workers

15. Facial Nerve Palsy references

1. Facial Nerve Palsy Following Administration of COVID-19 mRNA Vaccines: Analysis of Self-Report Database

2. COVID-19 Vaccination Association and Facial Nerve Palsy: A Case-Control Study

3. Sequential Contralateral Facial Nerve Palsy After First and Second Doses of COVID-19 Vaccine

4. Peripheral Facial Nerve Palsy After Vaccination with BNT162b2 (COVID-19)

5. Facial Nerve Palsy After Administration of COVID-19 mRNA Vaccines: Analysis of Self-Report Database

6. A Case of Acute Demyelinating Polyradiculoneuropathy with Bilateral Facial Palsy Following ChAdOx1 nCoV-19 Vaccination

16. Guillain-Barré Syndrome references

1. GM1 Ganglioside Antibody and COVID-19-Related Guillain-Barre Syndrome: Case Report, Systemic Review, and Implications for Vaccine Development

2. Guillain-Barré Syndrome After AstraZeneca COVID-19 Vaccination: Causal or Casual Association

3. Sensory Guillain-Barré Syndrome After ChAdOx1 nCov-19 Vaccine: Report of Two Cases and Review of the Literature

4. Guillain-Barré Syndrome After the First Dose of SARS-CoV-2 Vaccine: A Temporary Occurrence, Not a Causal Association

5. Guillain-Barré Syndrome Presenting as Facial Diplegia After Vaccination With COVID-19: A Case Report

6. Guillain-Barré Syndrome After the First Injection of ChAdOx1 nCoV-19 Vaccine: First Report

7. SARS-CoV-2 Vaccines Are Not Safe for Those With Guillain-Barre Syndrome Following Vaccination

8. Guillain Barré Syndrome After Vaccination with mRNA-1273 Against COVID-19

9. A Novel Case of Bifacial Diplegia Variant of Guillain-Barré Syndrome After Vaccination With Janssen COVID-19

10. Sensory Guillain-Barré Syndrome Following ChAdOx1 nCov-19 Vaccine: Report of Two Cases and Review of the Literature

11. Facial Diplegia: A Rare and Atypical Variant of Guillain-Barré Syndrome and the Ad26.COV2.S Vaccine

12. Guillain-Barré Syndrome After ChAdOx1 nCoV-19 COVID-19 Vaccination: A Case Series

13. AstraZeneca COVID-19 Vaccine and Guillain-Barré Syndrome in Tasmania: A Causal Link

14. COVID-19, Guillain-Barré and Vaccine: A Dangerous Mix

15. Guillain-Barré Syndrome After the First Dose of Pfizer-BioNTech COVID-19 Vaccine: Case Report and Review of Reported Cases

16. Guillain-Barre Syndrome After BNT162b2 COVID-19 Vaccine

17. COVID-19 Adenovirus Vaccines and Guillain-Barré Syndrome with Facial Palsy

18. Association of Receipt Association of Ad26.COV2.S COVID-19 Vaccine with Presumed Guillain-Barre Syndrome, February-July 2021

19. A Case of Guillain-Barré Syndrome After Pfizer-BioNTech COVID-19 Vaccine

20. Guillain-Barré Syndrome Associated with COVID-19 Vaccination

21. Rate of Recurrent Guillain-Barré Syndrome After COVID-19 BNT162b2 mRNA Vaccine

22. Guillain-Barre Syndrome After COVID-19 Vaccination in an Adolescent

23. Guillain-Barre Syndrome After ChAdOx1-S / nCoV-19 Vaccination

24. Guillain-Barre Syndrome After COVID-19 mRNA-1273 Vaccine: Case Report

25. Guillain-Barre Syndrome Following SARS-CoV-2 Vaccination in 19 Patients

26. Guillain-Barre Syndrome Presenting With Facial Diplegia Following Vaccination With COVID-19 in Two Patients

27. A Rare Case of Guillain-Barré Syndrome After COVID-19 Vaccination

28. Neurological Complications of COVID-19: Guillain-Barre Syndrome After Pfizer COVID-19 Vaccine

29. COVID-19 Vaccine Causing Guillain-Barre Syndrome, an Uncommon Potential Side Effect

30. Guillain-Barre Syndrome After the First Dose of COVID-19 Vaccination: Case Report

31. Guillain-Barre Syndrome After the First Injection of ChAdOx1 nCoV-19 Vaccine: First Report

32. A Case of Sensory Ataxic Guillain-Barre Syndrome With Immunoglobulin G Anti-GM1 Antibodies After First Dose of COVID-19 BNT162b2 mRNA Vaccine (Pfizer)

33. A Variant of Guillain-Barré Syndrome After SARS-CoV-2 Vaccination: AMSAN

34. A Rare Variant of Guillain-Barré Syndrome After Vaccination With Ad26.COV2.S

35. Guillain-Barré Syndrome After SARS-CoV-2 Vaccination in a Patient With Previous Vaccine-Associated Guillain-Barré Syndrome

36. Guillain-Barré Syndrome in an Australian State Using mRNA and Adenovirus-Vector SARS-CoV-2 Vaccines

37. Variant Guillain-Barré Syndrome Occurring After SARS-CoV-2 Vaccination

38. Guillain-Barre Syndrome With Axonal Variant Temporally Associated With Modern SARS-CoV-2 mRNA-Based Vaccine

39. Guillain-Barre Syndrome After the First Dose of SARS-CoV-2 Vaccine: A Temporary Occurrence, Not a Causal Association

40. SARS-CoV-2 Vaccines Can Be Complicated Not Only by Guillain-Barré Syndrome But Also by Distal Small Fiber Neuropathy

41. Clinical Variant of Guillain-Barré Syndrome With Prominent Facial Diplegia After AstraZeneca 2019 Coronavirus Disease Vaccine

42. Miller-Fisher Syndrome and Guillain-Barré Syndrome Overlap Syndrome in a Patient After Oxford-AstraZeneca SARS-CoV-2 Vaccination

43. Bilateral Facial Weakness With a Variant of Paresthesia of Guillain-Barre Syndrome After Vaxzevria COVID-19 Vaccine

17. Hemophagocytic Lymphohistiocytosis references

1. Hemophagocytic Lymphohistiocytosis After Vaccination With ChAdOx1 nCov-19

2. Hemophagocytic Lymphohistiocytosis Following COVID-19 Vaccination (ChAdOx1 nCoV-19)

18. Henoch-Schonlein Purpura references

1. A Rare Case of Henoch-Schönlein Purpura after a Case Report of COVID-19 Vaccine

2. Henoch-Schönlein Purpura Occurring after Vaccination with COVID-19

3. Henoch-Schönlein Purpura following the First Dose of COVID-19 Viral Vector Vaccine: Case Report

19. Immune-Mediated Disease Outbreaks references

1. Lobar Hemorrhage with Ventricular Rupture Shortly After the First Dose of an mRNA-Based SARS-CoV-2 Vaccine

2. Retinal Hemorrhage After SARS-CoV-2 Vaccination

3. Lobar Hemorrhage with Ventricular Rupture Shortly After the First Dose of a SARS-CoV-2 mRNA-Based SARS-CoV-2 Vaccine

4. Acral Hemorrhage After Administration of the Second Dose of SARS-CoV-2 Vaccine. A Post-Vaccination Reaction

5. Fatal Cerebral Hemorrhage After COVID-19 Vaccine

6. Intracerebral Hemorrhage Associated with Vaccine-Induced Thrombotic Thrombocytopenia After ChAdOx1 nCOVID-19 Vaccination in a Pregnant Woman

20. Immune-Mediated Hepatitis references

1. Autoimmune Hepatitis Developing After Coronavirus Disease Vaccine 2019 (COVID-19): Causality or Victim?

2. Autoimmune Hepatitis Triggered by Vaccination Against SARS-CoV-2

3. Acute Autoimmune-Like Hepatitis With Atypical Antimitochondrial Antibody After Vaccination With COVID-19 mRNA: A New Clinical Entity

4. Autoimmune Hepatitis After COVID Vaccine

5. Hepatitis C Virus Reactivation After COVID-19 Vaccination: A Case Report

6. Autoimmune Hepatitis Developing After ChAdOx1 nCoV-19 Vaccine (Oxford-AstraZeneca)

7. Autoimmune Hepatitis Triggered by SARS-CoV-2 Vaccination

8. Immune-Mediated Hepatitis With the Moderna Vaccine Is No Longer a Coincidence but Confirmed

21. Internal Bleeding references

1. Blood Clots and Bleeding Episodes after BNT162b2 and ChAdOx1 nCoV-19 Vaccination: Analysis of European Data

2. Association between ChAdOx1 nCoV-19 Vaccination and Bleeding Episodes: Large Population-Based Cohort Study

22. Intracerebral Haemorrhage references

1. Intracerebral Haemorrhage Due to Thrombosis With Thrombocytopenia Syndrome After COVID-19 Vaccination: The First Fatal Case in Korea

2. Intracerebral Haemorrhage Twelve Days After Vaccination With ChAdOx1 nCoV-19

3. Neurosurgical Considerations Regarding Decompressive Craniectomy for Intracerebral Hemorrhage After SARS-CoV-2 Vaccination in Vaccine-Induced Thrombotic Thrombocytopenia-VITT

4. First Dose of ChAdOx1 and BNT162b2 COVID-19 Vaccines and Thrombocytopenic, Thromboembolic, and Hemorrhagic Events in Scotland

5. Large Hemorrhagic Stroke After Vaccination Against ChAdOx1 nCoV-19: A Case Report

6. Major Hemorrhagic Stroke After ChAdOx1 nCoV-19 Vaccination: A Case Report

7. Aphasia Seven Days After the Second Dose of an mRNA-Based SARS-CoV-2 Vaccine. Brain MRI Revealed an Intracerebral Haemorrhage (ICBH) in the Left Temporal Lobe in a 52-Year-Old Man

8. Incidence of Acute Ischemic Stroke After Coronavirus Vaccination in Indonesia: Case Series

23. Lymphadenopathy references

1. Rare Case of Contralateral Supraclavicular Lymphadenopathy After Vaccination With COVID-19: Computed Tomography and Ultrasound Findings

2. COVID-19 mRNA Vaccination-Induced Lymphadenopathy Mimics Lymphoma Progression on FDG PET/CT

3. Lymphadenopathy in COVID-19 Vaccine Recipients: Diagnostic Dilemma in Oncology Patients

4. Hypermetabolic Lymphadenopathy After Administration of BNT162b2 mRNA Vaccine COVID-19: Incidence Assessed by [18 F] FDG PET-CT and Relevance for Study Interpretation

5. Lymphadenopathy After COVID-19 Vaccination: Review of Imaging Findings

6. Lymphadenopathy Associated With COVID-19 Vaccination on FDG PET/CT: Distinguishing Features in Adenovirus-Vectored Vaccine

7. COVID-19 Vaccination-Induced Lymphadenopathy in a Specialized Breast Imaging Clinic in Israel: Analysis of 163 Cases

8. Coronavirus Disease Vaccine 2019 Mimics Lymph Node Metastases in Patients Undergoing Skin Cancer Follow-Up: A Single-Center Study

9. COVID-19 Post-Vaccination Lymphadenopathy: Report of Fine-Needle Aspiration Biopsy Cytologic Findings

10. Regional Lymphadenopathy After COVID-19 Vaccination: Review of the Literature and Considerations for Patient Management in Breast Cancer Care

11. Adverse Events of COVID Injection That May Occur in Children. Acute-Onset Supraclavicular Lymphadenopathy Coincident With Intramuscular mRNA Vaccination Against COVID-19 May Be Related to the Injection Technique of the Vaccine, Spain, January and February 2021

12. Supraclavicular Lymphadenopathy After COVID-19 Vaccination in Korea: Serial Follow-Up by Ultrasonography

13. Oxford-AstraZeneca COVID-19 Vaccination Induced Lymphadenopathy on [18F] Choline PET/CT, Not Just an FDG Finding

14. A Case of Cervical Lymphadenopathy Following COVID-19 Vaccination

15. Unilateral Lymphadenopathy After COVID-19 Vaccination: A Practical Management Plan for Radiologists of All Specialties

16. Supraclavicular Lymphadenopathy After COVID-19 Vaccination: An Increasing Presentation in the Two-Week Wait Neck Lump Clinic

17. COVID-19 Vaccination and Lower Cervical Lymphadenopathy in Two-Week Neck Lump Clinic: A Follow-Up Audit

18. Cervical Lymphadenopathy After Coronavirus Disease Vaccination 2019: Clinical Features and Implications for Head and Neck Cancer Services

19. Lymphadenopathy Associated With the COVID-19 Vaccine

20. Evolution of Lymphadenopathy on PET/MRI Massive Cervical Lymphadenopathy Following Vaccination With COVID-19

21. Acute-Onset Supraclavicular Lymphadenopathy Coincident With Intramuscular mRNA Vaccination Against COVID-19 May Be Related to the Injection Technique of the Vaccine, Spain, January and February 2021

22. Supraclavicular Lymphadenopathy After COVID-19 Vaccination in Korea: Serial Follow-Up by Ultrasonography

23. Oxford-AstraZeneca COVID-19 Vaccination Induced Lymphadenopathy on [18F] Choline PET/CT, Not Just an FDG Finding

24. A Case of Cervical Lymphadenopathy Following COVID-19 Vaccination

25. Unilateral Lymphadenopathy After COVID-19 Vaccination: A Practical Management Plan for Radiologists of All Specialties

26. Supraclavicular Lymphadenopathy After COVID-19 Vaccination: An Increasing Presentation in the Two-Week Wait Neck Lump Clinic

27. COVID-19 Vaccination and Lower Cervical Lymphadenopathy in Two-Week Neck Lump Clinic: A Follow-Up Audit

28. Cervical Lymphadenopathy After Coronavirus Disease Vaccination 2019: Clinical Features and Implications for Head and Neck Cancer Services

29. Lymphadenopathy Associated With the COVID-19 Vaccine

30. Evolution of Lymphadenopathy on PET/MRI After COVID-19 Vaccination

31. Massive Cervical Lymphadenopathy Following Vaccination With COVID-19

32. COVID-19 Vaccine-Related Axillary and Cervical Lymphadenopathy in Patients With Current or Previous Breast Cancer and Other Malignancies: Cross-Sectional Imaging Findings on MRI, CT, and PET-CT

33. Supraclavicular Lymphadenopathy After COVID-19 Vaccination in Korea: Serial Follow-Up by Ultrasonography

34. Evolution of Lymphadenopathy at PET/MRI After COVID-19 Vaccination

24. Multiple Sclerosis references

1. Severe Relapse of Multiple Sclerosis after COVID-19 Vaccination: A Case Report

2. Acute Relapse and Impaired Immunization after COVID-19 Vaccination in a Patient with Multiple Sclerosis Treated with Rituximab

3. Humoral Response Induced by Prime-Boost Vaccination with ChAdOx1 nCoV-19 and BNT162b2 mRNA Vaccines in a Patient with Multiple Sclerosis Treated with Teriflunomide

4. Initial Clinical Manifestation of Multiple Sclerosis after Immunization with the Pfizer-BioNTech COVID-19 Vaccine

25. Myocarditis References

1. Myocarditis after mRNA vaccination against SARS-CoV-2, a case series

2. Myocarditis after immunization with COVID-19 mRNA vaccines in members of the US military

3. Association of myocarditis with the BNT162b2 messenger RNA COVID-19 vaccine in a case series of children

4. Acute symptomatic myocarditis in seven adolescents after Pfizer-BioNTech COVID-19 vaccination

5. Myocarditis and pericarditis after vaccination with COVID-19 mRNA: practical considerations for care providers

6. Myocarditis, pericarditis and cardiomyopathy after COVID-19 vaccination

7. Myocarditis with COVID-19 mRNA vaccines

8. Myocarditis and pericarditis after COVID-19 vaccination

9. Myocarditis temporally associated with COVID-19 vaccination

10. COVID-19 Vaccination Associated with Myocarditis in Adolescents

11. Acute myocarditis after administration of BNT162b2 vaccine against COVID-19

12. Temporal association between COVID-19 vaccine Ad26.COV2.S and acute myocarditis: case report and review of the literature

13. COVID-19 vaccine-induced myocarditis: a case report with review of the literature

14. Potential association between COVID-19 vaccine and myocarditis: clinical and CMR findings

15. Recurrence of acute myocarditis temporally associated with receipt of coronavirus mRNA disease vaccine 2019 (COVID-19) in a male adolescent

16. Fulminant myocarditis and systemic hyperinflammation temporally associated with BNT162b2 COVID-19 mRNA vaccination in two patients

17. Acute myocarditis after administration of BNT162b2 vaccine

18. Lymphohistocytic myocarditis after vaccination with COVID-19 Ad26.COV2.S viral vector

19. Myocarditis following vaccination with BNT162b2 in a healthy male

20. Acute myocarditis after Comirnaty (Pfizer) vaccination in a healthy male with previous SARS-CoV-2 infection

21. Acute myocarditis after vaccination with SARS-CoV-2 mRNA-1273 mRNA

22. Acute myocarditis after SARS-CoV-2 vaccination in a 24-year-old man

23. A series of patients with myocarditis after vaccination against SARS-CoV-2 with mRNA-1279 and BNT162b2

24. COVID-19 mRNA vaccination and myocarditis

25. COVID-19 vaccine and myocarditis

26. Epidemiology and clinical features of myocarditis/pericarditis before the introduction of COVID-19 mRNA vaccine in Korean children: a multicenter study

27. COVID-19 vaccines and myocarditis

28. Myocarditis and other cardiovascular complications of COVID-19 mRNA-based COVID-19 vaccines

29. Myocarditis and other cardiovascular complications of COVID-19 mRNA-based COVID-19 vaccines

30. Myocarditis, pericarditis, and cardiomyopathy after COVID-19 vaccination

31. Myocarditis with COVID-19 mRNA vaccines

32. Association of myocarditis with COVID-19 mRNA vaccine in children

33. Association of myocarditis with COVID-19 messenger RNA vaccine BNT162b2 in a case series of children

34. Myocarditis after immunization with COVID-19 mRNA vaccines in members of the U.S. military

35. Myocarditis occurring after immunization with COVID-19 mRNA-based COVID-19 vaccines

36. Myocarditis following immunization with Covid-19 mRNA

37. Patients with acute myocarditis after vaccination withCOVID-19 mRNA

38. Myocarditis associated with vaccination with COVID-19 mRNA

39. Symptomatic Acute Myocarditis in 7 Adolescents after Pfizer-BioNTech COVID-19 Vaccination

40. Cardiovascular magnetic resonance imaging findings in young adult patients with acute myocarditis after COVID-19 mRNA vaccination: a case series

41. Clinical Guidance for Young People with Myocarditis and Pericarditis after Vaccination with COVID-19 mRNA

42. Cardiac imaging of acute myocarditis after vaccination with COVID-19 mRNA

43. Case report: acute myocarditis after the second dose of mRNA-1273 SARS-CoV-2 mRNA vaccine

44. Myocarditis / pericarditis associated with COVID-19 vaccine

45. The new COVID-19 mRNA vaccine platform and myocarditis: clues to the possible underlying mechanism

46. Myocarditis associated with COVID-19 vaccination: echocardiographic, cardiac tomography, and magnetic resonance imaging findings

47. In-depth evaluation of a case of presumed myocarditis after the second dose of COVID-19 mRNA vaccine

48. Occurrence of acute infarct-like myocarditis after COVID-19 vaccination: just an accidental coincidence or rather a vaccination-associated autoimmune myocarditis?

49. Recurrence of acute myocarditis temporally associated with receipt of coronavirus mRNA disease vaccine 2019 (COVID-19) in a male adolescent

50. Myocarditis after SARS-CoV-2 vaccination: a vaccine-induced reaction?

51. Self-limited myocarditis presenting with chest pain and ST-segment elevation in adolescents after vaccination with the BNT162b2 mRNA vaccine

52. Biopsy-proven lymphocytic myocarditis after the first COVID-19 mRNA vaccination in a 40-year-old man: case report

53. Myocarditis and other cardiovascular complications of mRNA-based COVID-19 vaccines

54. Case report: acute myocarditis after the second dose of SARS-CoV-2 mRNA-1273 vaccine mRNA-1273

55. Acute myocardial infarction within 24 hours after COVID-19 vaccination.

56. Fulminant myocarditis and systemic hyperinflammation temporally associated with BNT162b2 COVID-19 mRNA vaccination in two patients.

57. Lymphohistocytic myocarditis after vaccination with the COVID-19 viral vector Ad26.COV2.S

58. Myocarditis associated with SARS-CoV-2 mRNA vaccination in children aged 12 to 17 years: stratified analysis of a national database

59. A report of myocarditis adverse events in the U.S. Vaccine Adverse Event Reporting System (VAERS) in association with COVID-19 injectable biologics

60. This study concludes that: "The vaccine was associated with an excess risk of myocarditis (1 to 5 events per 100,000 persons). The risk of this potentially serious adverse event and of many other serious adverse events increased substantially after SARS-CoV-2 infection"

61. Myocarditis associated with SARS-CoV-2 mRNA vaccination in children aged 12 to 17 years: stratified analysis of a national database.

62. Epidemiology of acute myocarditis/pericarditis in Hong Kong adolescents after co-vaccination

63. Myocarditis after 2019 coronavirus disease mRNA vaccine: a case series and determination of incidence rate.

64. Myocarditis and pericarditis after COVID-19 vaccination: inequalities in age and vaccine types.

65. Epidemiology and clinical features of myocarditis/pericarditis before the introduction of COVID-19 mRNA vaccine in Korean children: a multicenter study.

66. Shedding light on post-vaccination myocarditis and pericarditis in COVID-19 and non-COVID-19 vaccine recipients.

67. Myocarditis Following mRNA COVID-19 Vaccine

68. Myocarditis following BNT162b2 mRNA Covid-19 mRNA vaccine in Israel.

69. Myocarditis, pericarditis, and cardiomyopathy following COVID-19 vaccination.

70. Myocarditis and other cardiovascular complications of COVID-19 mRNA-based COVID-19 vaccines.

71. Possible Association Between COVID-19 Vaccine and Myocarditis: Clinical and CMR Findings.

72. Hypersensitivity Myocarditis and COVID-19 Vaccines.

73. Severe myocarditis associated with COVID-19 vaccine: zebra or unicorn?.

74. Acute myocardial infarction and myocarditis after COVID-19 vaccination.

75. Myocarditis after Covid-19 vaccination in a large healthcare organization.

76. Association of myocarditis with COVID-19 messenger RNA BNT162b2 vaccine in a case series of children.

77. Clinical suspicion of myocarditis temporally related to COVID-19 vaccination in adolescents and young adults.

78. STEMI mimicry: focal myocarditis in an adolescent patient after COVID-19 mRNA vaccination.

79. Myocarditis and pericarditis in association with COVID-19 mRNA vaccination: cases from a regional pharmacovigilance center.

80. Myocarditis after COVID-19 mRNA vaccines.

81. Patients with acute myocarditis after COVID-19 mRNA vaccination.

82. Myocarditis after COVID-19 vaccination: a case series.

83. Myocarditis associated with COVID-19 vaccination in adolescents.

84. Myocarditis findings on cardiac magnetic resonance imaging after vaccination with COVID-19 mRNA in adolescents.

85. Myocarditis after COVID-19 vaccination: magnetic resonance imaging study

86. Acute myocarditis after administration of the second dose of BNT162b2 COVID-19 vaccine.

87. Myocarditis after COVID-19 vaccination.

88. Case report: probable myocarditis after Covid-19 mRNA vaccine in a patient with arrhythmogenic left ventricular cardiomyopathy.

89. Acute myocarditis after administration of BNT162b2 vaccine against COVID-19.

90. Myocarditis associated with COVID-19 mRNA vaccination.

91. Acute myocarditis after COVID-19 vaccination: a case report

92. Acute myopericarditis after COVID-19 vaccination in adolescents.

93. Perimyocarditis in adolescents after Pfizer-BioNTech COVID-19 vaccination.

94. Acute myocarditis associated with anti-COVID-19 vaccination.

95. Myocarditis associated with COVID-19 vaccination: echocardiographic, cardiac CT, and MRI findings.

96. Acute symptomatic myocarditis in 7 adolescents after Pfizer-BioNTech COVID-19 vaccination.

97. Myocarditis and pericarditis in adolescents after First and second doses of COVID-19 mRNA vaccines

98. COVID 19 vaccine for adolescents. Concern for myocarditis and pericarditis.

99. Cardiac imaging of acute myocarditis after vaccination with COVID-19 mRNA

100. Myocarditis temporally associated with COVID-19 vaccination

101. Acute myocarditis associated with COVID-19 vaccination: report of a case

102. Myocarditis following vaccination with COVID-19 messenger RNA: a Japanese case series.

103. Myocarditis in the setting of a recent COVID-19 vaccination.

104. Acute myocarditis after a second dose of COVID-19 mRNA vaccine: report of two cases.

105. Prevalence of thrombocytopenia, antiplatelet factor 4 antibodies, and elevated D-dimer in Thais after vaccination with ChAdOx1 nCoV-19

106. Epidemiology of acute myocarditis/pericarditis in Hong Kong adolescents after co-vaccination

107. Myocarditis after 2019 coronavirus disease mRNA vaccine: a case series and incidence rate determination.

108. Myocarditis and pericarditis after COVID-19 vaccination: inequalities in age and vaccine types

109. Epidemiology and clinical features of myocarditis/pericarditis before the introduction of COVID-19 mRNA vaccine in Korean children

110. Shedding light on post-vaccination myocarditis and pericarditis in COVID-19 and non-COVID-19 vaccine recipients

111. Epidemiology of acute myocarditis/pericarditis in Hong Kong adolescents after co-vaccination

112. Myocarditis-induced sudden death after BNT162b2 COVID-19 mRNA vaccination in Korea: case report focusing on histopathological findings

113. Acute myocarditis after vaccination with COVID-19 mRNA in adults aged 18 years or older

114. Recurrence of acute myocarditis temporally associated with receipt of the 2019 coronavirus mRNA disease vaccine (COVID-19) in an adolescent male

115. Young male with myocarditis after mRNA-1273 coronavirus disease-2019 (COVID-19) mRNA vaccination

116. Acute myocarditis after SARS-CoV-2 vaccination in a 24-year-old male

117. Ga-DOTATOC digital PET images of inflammatory cell infiltrates in myocarditis after vaccination with COVID-19

118. Occurrence of acute infarct-like myocarditis after vaccination with COVID-19: just an accidental coincidence or rather a vaccination-associated autoimmune myocarditis?

119. Self-limited myocarditis presenting with chest pain and ST-segment elevation in adolescents after vaccination with BNT162b2 mRNA vaccine

120. Myocarditis Following Immunization with COVID-19 mRNA Vaccines in Members of the U.S. Military

121. Myocarditis after BNT162b2 vaccination in a healthy male

122. Acute myocarditis after SARS-CoV-2 mRNA-1273 mRNA vaccination

123. Biopsy-proven lymphocytic myocarditis after the first vaccination with COVID-19 mRNA in a 40-year-old man: case report

124. Multimodality imaging and histopathology in a young man presenting with fulminant lymphocytic myocarditis and cardiogenic shock after vaccination with mRNA-1273

125. Acute myocarditis after Comirnaty vaccination in a healthy male with previous SARS-CoV-2 infection

126. Acute myocarditis in a young adult two days after vaccination with Pfizer

127. Case report: acute fulminant myocarditis and cardiogenic shock after messenger RNA coronavirus vaccination in 2019 requiring extracorporeal cardiopulmonary resuscitation

128. Acute myocarditis after 2019 coronavirus disease vaccination

129. A series of patients with myocarditis after vaccination against SARS-CoV-2 with mRNA-1279 and BNT162b2

130. Acute myocarditis defined after vaccination with 2019 mRNA of coronavirus disease

131. Biventricular systolic dysfunction in acute myocarditis after SARS-CoV-2 mRNA-1273 vaccination

132. Myocarditis following COVID-19 vaccination: MRI study

133. Acute myocarditis after COVID-19 vaccination: case report

134. Association of myocarditis with COVID-19 messenger RNA BNT162b2 vaccine COVID-19 in a case series of children

135. Clinical suspicion of myocarditis temporally related to COVID-19 vaccination in adolescents and young adults

136. Myocarditis following vaccination with Covid-19 in a large healthcare organization

137. Myocarditis and pericarditis in adolescents after the first and second doses of COVID-19 mRNA vaccines

138. Myocarditis after SARS-CoV-2 mRNA vaccination, a case series

139. Epidemiology of myocarditis and pericarditis following mRNA vaccines in Ontario, Canada: by vaccine product, schedule, and interval

140. Acute myocardial infarction and myocarditis after COVID-19 vaccination

141. Fulminant myocarditis and systemic hyperinflammation temporally associated with BNT162b2 mRNA COVID-19 vaccination in two patients - Abbate, A., Gavin, J., Madanchi, N., Kim, C., Shah, P. R., Klein, K., . . . Danielides, S. (2021). Int J Cardiol, 340, 119-121.

142. Myocarditis following COVID-19 mRNA vaccination - Abu Mouch, S., Roguin, A., Hellou, E., Ishai, A., Shoshan, U., Mahamid, L., . . . Berar Yanay, N. (2021). Vaccine, 39(29), 3790-3793.

143. Myocarditis following COVID-19 vaccination - Albert, E., Aurigemma, G., Saucedo, J., & Gerson, D. S. (2021). Radiol Case Rep, 16(8), 2142-2145.

144. Acute Myocardial Infarction and Myocarditis following COVID-19 Vaccination - Aye, Y. N., Mai, A. S., Zhang, A., Lim, O. Z. H., Lin, N., Ng, C. H., . . . Chew, N. W. S. (2021). QJM.

145. STEMI Mimic: Focal Myocarditis in an Adolescent Patient After mRNA COVID-19 Vaccine - Azir, M., Inman, B., Webb, J., & Tannenbaum, L. (2021). J Emerg Med, 61(6), e129-e132.

146. Myocarditis With COVID-19 mRNA Vaccines - Bozkurt, B., Kamat, I., & Hotez, P. J. (2021). Circulation, 144(6), 471-484.

147. COVID 19 Vaccine for Adolescents. Concern about Myocarditis and Pericarditis - Calcaterra, G., Mehta, J. L., de Gregorio, C., Butera, G., Neroni, P., Fanos, V., & Bassareo, P. P. (2021). Pediatr Rep, 13(3), 530-533.

148. Occurrence of acute infarct-like myocarditis following COVID-19 vaccination: just an accidental co-incidence or rather vaccination-associated autoimmune myocarditis? - Chamling, B., Vehof, V., Drakos, S., Weil, M., Stalling, P., Vahlhaus, C., . . . Yilmaz, A. (2021). Clin Res Cardiol, 110(11), 1850-1854.

149. Cardiac MRI Findings of Myocarditis After COVID-19 mRNA Vaccination in Adolescents - Chelala, L., Jeudy, J., Hossain, R., Rosenthal, G., Pietris, N., & White, C. (2021). AJR Am J Roentgenol.

150. Myocarditis-induced Sudden Death after BNT162b2 mRNA COVID-19 Vaccination in Korea: Case Report Focusing on Histopathological Findings - Choi, S., Lee, S., Seo, J. W., Kim, M. J., Jeon, Y. H., Park, J. H., . . . Yeo, N. S. (2021). J Korean Med Sci, 36(40), e286.

151. Epidemiology of Acute Myocarditis/Pericarditis in Hong Kong Adolescents Following Comirnaty Vaccination - Chua, G. T., Kwan, M. Y. W., Chui, C. S. L., Smith, R. D., Cheung, E. C., Tian, T., . . . Ip, P. (2021). Clin Infect Dis.

152. Should T2 mapping be used in cases of recurrent myocarditis to differentiate between acute inflammation and chronic scar? - Clarke, R., & Ioannou, A. (2021). J Pediatr.

153. Myocarditis and Pericarditis Following mRNA COVID-19 Vaccination: What Do We Know So Far? - Das, B. B., Moskowitz, W. B., Taylor, M. B., & Palmer, A. (2021). Children (Basel), 8(7).

154. A Series of Patients With Myocarditis Following SARS-CoV-2 Vaccination With mRNA-1279 and BNT162b2 - Dickey, J. B., Albert, E., Badr, M., Laraja, K. M., Sena, L. M., Gerson, D. S., . . . Aurigemma, G. P. (2021). JACC Cardiovasc Imaging, 14(9), 1862-1863.

155. Biopsy-proven lymphocytic myocarditis following thefirst mRNA COVID-19 vaccination in a 40-year-old male: case report - Ehrlich, P., Klingel, K., Ohlmann-Knafo, S., Huttinger, S., Sood, N., Pickuth, D., & Kindermann, M. (2021). Clin Res Cardiol, 110(11), 1855-1859.

156. Acute myocarditis in a young adult two days after Pfizer vaccination - Facetti, S., Giraldi, M., Vecchi, A. L., Rogiani, S., & Nassiacos, D. (2021). G Ital Cardiol (Rome), 22(11), 891-893.

157. Myocarditis and Pericarditis in Adolescents after First and Second doses of mRNA COVID-19 Vaccines - Foltran, D., Delmas, C., Flumian, C., De Paoli, P., Salvo, F., Gautier, S., . . . Montastruc, F. (2021). Eur Heart J Qual Care Clin Outcomes.

158. Use of mRNA COVID-19 Vaccine After Reports of Myocarditis Among Vaccine Recipients: Update from the Advisory Committee on Immunization Practices – United States, June 2021 - Gargano, J. W., Wallace, M., Hadler, S. C., Langley, G., Su, J. R., Oster, M. E., . . . Oliver, S. E. (2021). MMWR Morb Mortal Wkly Rep, 70(27), 977-982.

159. A Late Presentation of COVID-19 Vaccine-Induced Myocarditis - Gautam, N., Saluja, P., Fudim, M., Jambhekar, K., Pandey, T., & Al’Aref, S. (2021). Cureus, 13(9), e17890.

160. Myocarditis after vaccination against COVID-19 - Gellad, W. F. (2021). BMJ, 375, n3090.

161. Myocarditis with the Pfizer/BioNTech and Moderna COVID-19 vaccines - In brief: Myocarditis with the Pfizer/BioNTech and Moderna COVID-19 vaccines. (2021). Med Lett Drugs Ther, 63(1629), e9.

162. Myocarditis should be considered in those with a troponin rise and unobstructed coronary arteries following Pfizer-BioNTech COVID-19 vaccination - Ioannou, A. (2021a). QJM. doi:10.1093/qjmed/hcab231.

163. T2 mapping should be utilized in cases of suspected myocarditis to confirm an acute inflammatory process - Ioannou, A. (2021b). QJM. doi:10.1093/qjmed/hcab326.

164. Myocarditis Following COVID-19 Vaccination - Isaak, A., Feisst, A., & Luetkens, J. A. (2021). Radiology, 301(1), E378-E379. doi:10.1148/radiol.2021211766.

165. Myocarditis and pericarditis in association with COVID-19 mRNA-vaccination: cases from a regional pharmacovigilance centre - Istampoulouoglou, I., Dimitriou, G., Spani, S., Christ, A., Zimmermanns, B., Koechlin, S., . . . Leuppi-Taegtmeyer, A. B. (2021). Glob Cardiol Sci Pract, 2021(3), e202118. doi:10.21542/gcsp.2021.18.

166. COVID-19 Vaccination-Associated Myocarditis in Adolescents - Jain, S. S., Steele, J. M., Fonseca, B., Huang, S., Shah, S., Maskatia, S. A., . . . Grosse-Wortmann, L. (2021). Pediatrics, 148(5). doi:10.1542/peds.2021-053427.

167. Young Male With Myocarditis Following mRNA-1273 Vaccination Against Coronavirus Disease-2019 (COVID-19) - Kaneta, K., Yokoi, K., Jojima, K., Kotooka, N., & Node, K. (2021). Circ J. doi:10.1253/circj.CJ-21-0818.

168. Myocarditis following COVID-19 vaccination - Kaul, R., Sreenivasan, J., Goel, A., Malik, A., Bandyopadhyay, D., Jin, C., . . . Panza, J. A. (2021). Int J Cardiol Heart Vasc, 36, 100872. doi:10.1016/j.ijcha.2021.100872.

169. Patients With Acute Myocarditis Following mRNA COVID-19 Vaccination - Kim, H. W., Jenista, E. R., Wendell, D. C., Azevedo, C. F., Campbell, M. J., Darty, S. N., . . . Kim, R. J. (2021). JAMA Cardiol, 6(10), 1196-1201. doi:10.1001/jamacardio.2021.2828.

170. Cardiac Imaging of Acute Myocarditis Following COVID-19 mRNA Vaccination - Kim, I. C., Kim, H., Lee, H. J., Kim, J. Y., & Kim, J. Y. (2021). J Korean Med Sci, 36(32), e229. doi:10.3346/jkms.2021.36.e229.

171. Myocarditis following mRNA vaccination against SARS-CoV-2, a case series - King, W. W., Petersen, M. R., Matar, R. M., Budweg, J. B., Cuervo Pardo, L., & Petersen, J. W. (2021). Am Heart J Plus, 8, 100042. doi:10.1016/j.ahjo.2021.100042.

172. mRNA COVID vaccine and myocarditis in adolescents - Kwan, M. Y. W., Chua, G. T., Chow, C. B., Tsao, S. S. L., To, K. K. W., Yuen, K. Y., . . . Ip, P. (2021). Hong Kong Med J, 27(5), 326-327. doi:10.12809/hkmj215120.

173. Reply to “Letter to the editor: Myocarditis should be considered in those with a troponin rise and unobstructed coronary arteries following Pfizer-BioNTech COVID-19 vaccination” - Lee, E., Chew, N. W. S., Ng, P., & Yeo, T. J. (2021). QJM. doi:10.1093/qjmed/hcab232.

174. Myocarditis following COVID-19 vaccination – A case series - Levin, D., Shimon, G., Fadlon-Derai, M., Gershovitz, L., Shovali, A., Sebbag, A., . . . Gordon, B. (2021). Vaccine, 39(42), 6195-6200. doi:10.1016/j.vaccine.2021.09.004.

175. Myocarditis and Pericarditis following COVID-19 Vaccination: Inequalities in Age and Vaccine Types - Li, M., Yuan, J., Lv, G., Brown, J., Jiang, X., & Lu, Z. K. (2021). J Pers Med, 11(11). doi:10.3390/jpm11111106.

176. Case Report: Acute Fulminant Myocarditis and Cardiogenic Shock After Messenger RNA Coronavirus Disease 2019 Vaccination Requiring Extracorporeal Cardiopulmonary Resuscitation - Lim, Y., Kim, M. C., Kim, K. H., Jeong, I. S., Cho, Y. S., Choi, Y. D., & Lee, J. E. (2021). Front Cardiovasc Med, 8, 758996. doi:10.3389/fcvm.2021.758996.

177. Myocarditis and Pericarditis After COVID-19 mRNA Vaccination: Practical Considerations for Care Providers - Luk, A., Clarke, B., Dahdah, N., Ducharme, A., Krahn, A., McCrindle, B., . . . McDonald, M. (2021). Can J Cardiol, 37(10), 1629-1634. doi:10.1016/j.cjca.2021.08.001.

178. Myocarditis after BNT162b2 mRNA Vaccine against Covid-19 in Israel - Mevorach, D., Anis, E., Cedar, N., Bromberg, M., Haas, E. J., Nadir, E., . . . Alroy-Preis, S. (2021). N Engl J Med, 385(23), 2140-2149. doi:10.1056/NEJMoa2109730.

179. Recurrence of Acute Myocarditis Temporally Associated with Receipt of the mRNA Coronavirus Disease 2019 (COVID-19) Vaccine in a Male Adolescent - Minocha, P. K., Better, D., Singh, R. K., & Hoque, T. (2021). J Pediatr, 238, 321-323. doi:10.1016/j.jpeds.2021.06.035.

180. Myocarditis Following Immunization With mRNA COVID-19 Vaccines in Members of the US Military - Montgomery, J., Ryan, M., Engler, R., Hoffman, D., McClenathan, B., Collins, L., . . . Cooper, L. T., Jr. (2021). JAMA Cardiol, 6(10), 1202-1206. doi:10.1001/jamacardio.2021.2833.

181. Myocarditis Following a COVID-19 Messenger RNA Vaccination: A Japanese Case Series - Murakami, Y., Shinohara, M., Oka, Y., Wada, R., Noike, R., Ohara, H., . . . Ikeda, T. (2021). Intern Med. doi:10.2169/internalmedicine.8731-21.

182. Acute Myocarditis Associated with COVID-19 Vaccination: A Case Report - Nagasaka, T., Koitabashi, N., Ishibashi, Y., Aihara, K., Takama, N., Ohyama, Y., . . . Kaneko, Y. (2021). J Cardiol Cases. doi:10.1016/j.jccase.2021.11.006.

183. Epidemiology and Clinical Features of Myocarditis/Pericarditis before the Introduction of mRNA COVID-19 Vaccine in Korean Children: a Multicenter Study - Park, H., Yun, K. W., Kim, K. R., Song, S. H., Ahn, B., Kim, D. R., . . . Kim, Y. J. (2021). J Korean Med Sci, 36(32), e232. doi:10.3346/jkms.2021.36.e232.

184. Self-limited myocarditis presenting with chest pain and ST segment elevation in adolescents after vaccination with the BNT162b2 mRNA vaccine - Park, J., Brekke, D. R., & Bratincsak, A. (2021). Cardiol Young, 1-doi:10.1017/S1047951121002547.

185. Cardiovascular magnetic resonance findings in young adult patients with acute myocarditis following mRNA COVID-19 vaccination: a case - Patel, Y. R., Louis, D. W., Atalay, M., Agarwal, S., & Shah, N. R. (2021). J Cardiovasc Magn Reson, 23(1), 101. doi:10.1186/s12968-021-00795-1.

186. Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection - Patone, M., Mei, X. W., Handunnetthi, L., Dixon, S., Zaccardi, F., Shankar-Hari, M., . . . Hippisley-Cox, J. (2021). Nat Med. doi:10.1038/s41591-021-01630-1.

187. Acute myocarditis following Comirnaty vaccination in a healthy man with previous SARS-CoV-2 infection - Patrignani, A., Schicchi, N., Calcagnoli, F., Falchetti, E., Ciampani, N., Argalia, G., & Mariani, A. (2021). Radiol Case Rep, 16(11), 3321-3325. doi:10.1016/j.radcr.2021.07.082.

188. Myocarditis Following COVID-19 mRNA Vaccine: A Case Series and Incidence Rate Determination - Perez, Y., Levy, E. R., Joshi, A. Y., Virk, A., Rodriguez-Porcel, M., Johnson, M., . . . Swift, M. D. (2021). Clin Infect Dis. doi:10.1093/cid/ciab926.

189. Myocarditis following COVID-19 vaccination: magnetic resonance imaging study - Shiyovich, A., Witberg, G., Aviv, Y., Eisen, A., Orvin, K., Wiessman, M., . . . Hamdan, A. (2021). Eur Heart J Cardiovasc Imaging. doi:10.1093/ehjci/jeab230.

190. Acute Myocarditis Following COVID-19 mRNA Vaccination in Adults Aged 18 Years or Older - Simone, A., Herald, J., Chen, A., Gulati, N., Shen, A. Y., Lewin, B., & Lee, M. S. (2021). JAMA Intern Med, 181(12), 1668-1670. doi:10.1001/jamainternmed.2021.5511.

191. Risk of Myocarditis from COVID-19 Infection in People Under Age 20: A Population-Based Analysis - Singer, M. E., Taub, I. B., & Kaelber, D. C. (2021). medRxiv. doi:10.1101/2021.07.23.21260998.

192. Myocarditis Associated with mRNA COVID-19 Vaccination - Starekova, J., Bluemke, D. A., Bradham, W. S., Grist, T. M., Schiebler, M. L., & Reeder, S. B. (2021). Radiology, 301(2), E409-E411. doi:10.1148/radiol.2021211430.

193. Temporal association between the COVID-19 Ad26.COV2.S vaccine and acute myocarditis: A case report and literature review - Sulemankhil, I., Abdelrahman, M., & Negi, S. I. (2021). Cardiovasc Revasc Med. doi:10.1016/j.carrev.2021.08.012.

194. Case report: acute myocarditis following the second dose of mRNA-1273 SARS-CoV-2 vaccine - Tailor, P. D., Feighery, A. M., El-Sabawi, B., & Prasad, A. (2021). Eur Heart J Case Rep, 5(8), ytab319. doi:10.1093/ehjcr/ytab319.

195. Eosinophilic Myocarditis Following Coronavirus Disease 2019 (COVID-19) Vaccination - Takeda, M., Ishio, N., Shoji, T., Mori, N., Matsumoto, M., & Shikama, N. (2021). Circ J. doi:10.1253/circj.CJ-21-935.

196. Clinically Suspected Myocarditis Temporally Related to COVID-19 Vaccination in Adolescents and Young Adults - Truong, D. T., Dionne, A., Muniz, J. C., McHugh, K. E., Portman, M. A., Lambert, L. M., . . . Newburger, J. W. (2021). Circulation. doi:10.1161/CIRCULATIONAHA.121.056583.

197. Myocarditis and Other Cardiovascular Complications of the mRNA-Based COVID-19 Vaccines - Vidula, M. K., Ambrose, M., Glassberg, H., Chokshi, N., Chen, T., Ferrari, V. A., & Han, Y. (2021). Cureus, 13(6), e15576. doi:10.7759/cureus.15576.

198. Myocarditis Following mRNA COVID-19 Vaccine - Visclosky, T., Theyyunni, N., Klekowski, N., & Bradin, S. (2021). Pediatr Emerg Care, 37(11), 583-584. doi:10.1097/PEC.0000000000002557.

199. Myocarditis after BNT162b2 vaccination in a healthy male - Watkins, K., Gri몭 n, G., Septaric, K., & Simon, E. L. (2021). Am J Emerg Med, 50, 815 e811-815 e812. doi:10.1016/j.ajem.2021.06.051.

200. Myocarditis after Covid-19 Vaccination in a Large Health Care Organization - Witberg, G., Barda, N., Hoss, S., Richter, I., Wiessman, M., Aviv, Y., . . . Kornowski, R. (2021). N Engl J Med, 385(23), 2132-2139. doi:10.1056/NEJMoa2110737.

201. Myocarditis with the Pfizer/BioNTech and Moderna COVID-19 vaccines (2021). Med Lett Drugs Ther, 63(1629), e9. Retrieved from PubMed

202. Myocarditis should be considered in those with a troponin rise and unobstructed coronary arteries following Pfizer-BioNTech COVID-19 vaccination. QJM. doi:10.1093/qjmed/hcab231. Author: Ioannou, A.

203. Myocarditis Following COVID-19 Vaccination. Radiology, 301(1), E378-E379. doi:10.1148/radiol.2021211766. Authors: Isaak, A., Feisst, A., & Luetkens, J. A.

204. Myocarditis and pericarditis in association with COVID-19 mRNA-vaccination: cases from a regional pharmacovigilance centre. Glob Cardiol Sci Pract, 2021(3), e202118. doi:10.21542/gcsp.2021.18. Authors: Istampoulouoglou, I., Dimitriou, G., Spani, S., Christ, A., Zimmermanns, B., Koechlin, S., . . . Leuppi-Taegtmeyer, A. B.

205. COVID-19 Vaccination-Associated Myocarditis in Adolescents. Pediatrics, 148(5). doi:10.1542/peds.2021-053427. Authors: Jain, S. S., Steele, J. M., Fonseca, B., Huang, S., Shah, S., Maskatia, S. A., . . . Grosse-Wortmann, L.

206. Young Male With Myocarditis Following mRNA-1273 Vaccination Against Coronavirus Disease-2019 (COVID-19). Circ J. doi:10.1253/circj.CJ-21-0818. Authors: Kaneta, K., Yokoi, K., Jojima, K., Kotooka, N., & Node, K.

207. Myocarditis following COVID-19 vaccination. Int J Cardiol Heart Vasc, 36, 100872. doi:10.1016/j.ijcha.2021.100872. Authors: Kaul, R., Sreenivasan, J., Goel, A., Malik, A., Bandyopadhyay, D., Jin, C., . . . Panza, J. A.

208. Patients With Acute Myocarditis Following mRNA COVID-19 Vaccination. JAMA Cardiol, 6(10), 1196-1201. doi:10.1001/jamacardio.2021.2828. Authors: Kim, H. W., Jenista, E. R., Wendell, D. C., Azevedo, C. F., Campbell, M. J., Darty, S. N., . . . Kim, R. J.

209. Cardiac Imaging of Acute Myocarditis Following COVID-19 mRNA Vaccination. J Korean Med Sci, 36(32), e229.doi:10.3346/jkms.2021.36.e229. Authors: Kim, I. C., Kim, H., Lee, H. J., Kim, J. Y., & Kim, J. Y.

210. Myocarditis following mRNA vaccination against SARS-CoV-2, a case series. Am Heart J Plus, 8, 100042. doi:10.1016/j.ahjo.2021.100042. Authors: King, W. W., Petersen, M. R., Matar, R. M., Budweg, J. B., Cuervo Pardo, L., & Petersen, J. W.

211. mRNA COVID vaccine and myocarditis in adolescents. Hong Kong Med J, 27(5), 326-327. doi:10.12809/hkmj215120. Authors: Kwan, M. Y. W., Chua, G. T., Chow, C. B., Tsao, S. S. L., To, K. K. W., Yuen, K. Y., . . . Ip, P.

212. Reply to “Letter to the editor: Myocarditis should be considered in those with a troponin rise and unobstructed coronary arteries following PfizerBioNTech COVID-19 vaccination”. QJM.doi:10.1093/qjmed/hcab232. Authors: Lee, E., Chew, N. W. S., Ng, P., & Yeo, T. J.

213. Myocarditis following COVID-19 vaccination – A case series. Vaccine, 39(42), 6195-6200.doi:10.1016/j.vaccine.2021.09.004. Authors: Levin, D., Shimon, G., Fadlon-Derai, M., Gershovitz, L., Shovali, A., Sebbag, A., . . . Gordon, B.

214. Myocarditis and Pericarditis following COVID-19 Vaccination: Inequalities in Age and Vaccine Types. J Pers Med, 11(11). doi:10.3390/jpm11111106. Authors: Li, M., Yuan, J., Lv, G., Brown, J., Jiang, X., & Lu, Z. K.

215. Acute Fulminant Myocarditis and Cardiogenic Shock After Messenger RNA Coronavirus Disease 2019 Vaccination Requiring Extracorporeal Cardiopulmonary Resuscitation. Front Cardiovasc Med, 8, 758996. doi:10.3389/fcvm.2021.758996. Authors: Lim, Y., Kim, M. C., Kim, K. H., Jeong, I. S., Cho, Y. S., Choi, Y. D., & Lee, J. E.

216. Myocarditis and Pericarditis After COVID-19 mRNA Vaccination: Practical Considerations for Care Providers. Can J Cardiol, 37(10), 1629-1634.doi:10.1016/j.cjca.2021.08.001. Authors: Luk, A., Clarke, B., Dahdah, N., Ducharme, A., Krahn, A., McCrindle, B., . . . McDonald, M.

217. Myocarditis after BNT162b2 mRNA Vaccine against Covid-19 in Israel. N Engl J Med, 385(23), 2140-2149. doi:10.1056/NEJMoa2109730. Authors: Mevorach, D., Anis, E., Cedar, N., Bromberg, M., Haas, E. J., Nadir, E., . . . Alroy-Preis, S.

218. Recurrence of Acute Myocarditis Temporally Associated with Receipt of the mRNA Coronavirus Disease 2019 (COVID-19) Vaccine in a Male Adolescent. J Pediatr, 238, 321-323.doi:10.1016/j.jpeds.2021.06.035. Authors: Minocha, P. K., Better, D., Singh, R. K., & Hoque, T.

219. Myocarditis Following Immunization With mRNA COVID-19 Vaccines in Members of the US Military. JAMA Cardiol, 6(10), 1202-1206.doi:10.1001/jamacardio.2021.2833. Authors: Montgomery, J., Ryan, M., Engler, R., Hoffman, D., McClenathan, B., Collins, L., . . . Cooper, L. T., Jr.

220. Myocarditis Following a COVID-19 Messenger RNA Vaccination: A Japanese Case Series. Intern Med. doi:10.2169/internalmedicine.8731-21. Authors: Murakami, Y., Shinohara, M., Oka, Y., Wada, R., Noike, R., Ohara, H., . . . Ikeda, T.

221. Acute Myocarditis Associated with COVID-19 Vaccination: A Case Report. Authors: Nagasaka, T., Koitabashi, N., Ishibashi, Y., Aihara, K., Takama, N., Ohyama, Y., . . . Kaneko, Y. Published in J Cardiol Cases. doi:10.1016/j.jccase.2021.11.006.

222. Premature Myocardial Infarction or Side Effect of COVID-19 Vaccine.

223. The Culprit.

224. A Case of Acute Encephalopathy and Non-ST-Segment Elevation Myocardial Infarction after Vaccination with mRNA-1273: Possible Adverse Effect.

225. Acute Myocardial Infarction within 24 Hours after COVID-19 Vaccination: Is Kounis Syndrome Clinical and Histopathologic Spectrum of Delayed Adverse Skin Reactions after COVID-19 Vaccination.

226. Features of Inflammatory Heart Reactions Following mRNA COVID-19 Vaccination at a Global Level. Authors: Chouchana, L., Blet, A., Al-Khalaf, M., Kaffl, T. S., Nair, G., Robblee, J., . . . Liu, P. P. Published in Clin Pharmacol Ther. doi:10.1002/cpt.2499.

227. Acute Fulminant Myocarditis and Cardiogenic Shock After Messenger RNA Coronavirus Disease 2019 Vaccination Requiring Extracorporeal Cardiopulmonary Resuscitation.

228. Lymphohistocytic Myocarditis after Ad26.COV2.S Viral Vector COVID-19 Vaccination.

26. Myopericarditis

1. Myopericarditis after Pfizer mRNA COVID-19 Vaccination in Adolescents

2. Myopericarditis after Vaccination with COVID-19 mRNA in Adolescents 12 to 18 Years of Age

3. Important Information on Myopericarditis after Vaccination with Pfizer COVID-19 mRNA in Adolescents

4. Insights from a Murine Model of COVID-19 mRNA Vaccine-Induced Myopericarditis: Could Accidental Intravenous Injection of a Vaccine Induce Myopericarditis

5. Acute Myocarditis after Administration of BNT162b2 Vaccine against COVID-19

6. Insights from a Murine Model of Myopericarditis Induced by COVID-19 mRNA Vaccine: Could Accidental Intravenous Injection of a Vaccine Induce Myopericarditis

7. COVID-19 mRNA Vaccination and Development of CMR-Confirmed Myopericarditis

8. Intravenous Injection of Coronavirus Disease 2019 (COVID-19) mRNA Vaccine Can Induce Acute Myopericarditis in a Mouse Model

9. Myopericarditis in a Previously Healthy Adolescent Male after COVID-19 Vaccination: Case Report

10. Report of a Case of Myopericarditis after Vaccination with BNT162b2 COVID-19 mRNA in a Young Korean Male

11. Myopericarditis after Pfizer Messenger Ribonucleic Acid Coronavirus Disease Vaccine in Adolescents

12. Acute Myopericarditis after COVID-19 Vaccine in Adolescents

13. Population-based Incidence of Myopericarditis After COVID-19 Vaccination in Danish Adolescents

14. Myopericarditis After the Pfizer Messenger Ribonucleic Acid Coronavirus Disease Vaccine in Adolescents

15. mRNA Coronavirus-19 Vaccine-Associated Myopericarditis in Adolescents: A Survey Study

16. Important Insights into Myopericarditis after the Pfizer mRNA COVID-19 Vaccination in Adolescents

17. Myopericarditis in a Previously Healthy Adolescent Male Following COVID-19 Vaccination: A Case Report

18. Recurrence of Myopericarditis Following mRNA COVID-19 Vaccination in a Male Adolescent

19. Myopericarditis After Messenger RNA Coronavirus Disease 2019 Vaccination in Adolescents 12 to 18 Years of Age

20. Influenza Vaccination and Myo-Pericarditis in Patients Receiving Immune Checkpoint Inhibitors

21. Myopericarditis in a Previously Healthy Adolescent Male After COVID-19 Vaccination: Case Report

27. Nephrotic Syndrome references

1. Nephrotic Syndrome After ChAdOx1 nCoV-19 Vaccine Against SARS-CoV-2

2. New-Onset Nephrotic Syndrome After Janssen COVID-19 Vaccination: Case Report and Literature Review

3. Hematuria, a Generalized Petechial Rash, and Headaches After Oxford AstraZeneca ChAdOx1 nCoV-19 Vaccination

4. A Case of Outbreak of Macroscopic Hematuria and IgA Nephropathy After SARS-CoV-2 Vaccination

28. Neurological Symptoms references

1. Neurological Symptoms and Neuroimaging Alterations Related to COVID-19 Vaccine: Cause or Coincidence

2. Neurological Symptoms and Neuroimaging Alterations Related to COVID-19 Vaccine: Cause or Coincidence?

3. Spectrum of Neurological Complications After COVID-19 Vaccination

4. Non-hospital Observational Study of Neurological Disorders in Patients Recently Vaccinated with COVID-19 mRNA Vaccines

5. Neurological Side Effects of SARS-CoV-2 Vaccines

6. Neurological Complications After the First Dose of COVID-19 Vaccines and SARS-CoV-2 Infection

29. Oculomotor Paralysis references

1. Transient oculomotor paralysis after administration of RNA-1273 messenger vaccine for SARS-CoV-2 diplopia after COVID-19 vaccine

30. Pericarditis references

1. Myocarditis and Pericarditis After Vaccination with COVID-19 mRNA: Practical Considerations for Care Providers

2. Myocarditis, Pericarditis, and Cardiomyopathy After COVID-19 Vaccination

3. Myocarditis and Pericarditis After COVID-19 Vaccination

4. Pericarditis After Administration of BNT162b2 mRNA COVID-19 mRNA Vaccine

5. Epidemiology and Clinical Features of Myocarditis/Pericarditis Before the Introduction of COVID-19 mRNA Vaccine in Korean Children: A Multicenter Study

6. Myocarditis, Pericarditis, and Cardiomyopathy After COVID-19 Vaccination

7. Clinical Guidance for Young People with Myocarditis and Pericarditis After Vaccination with COVID-19 mRNA

8. Myocarditis/Pericarditis Associated with COVID-19 Vaccine

9. Acute Myocarditis After the Second Dose of SARS-CoV-2 Vaccine: Serendipity or Causal Relationship

10. Pericarditis After Administration of COVID-19 mRNA BNT162b2 Vaccine

11. Unusual Presentation of Acute Pericarditis After Vaccination Against SARS-COV-2 mRNA-1237 Modern

12. A Case Series of Acute Pericarditis After Vaccination with COVID-19 in the Context of Recent Reports from Europe and the United States

13. Acute Pericarditis and Cardiac Tamponade After Vaccination with Covid-19

14. Pericarditis After Administration of the BNT162b2 mRNA Vaccine COVID-19

15. Case Report: Symptomatic Pericarditis Post COVID-19 Vaccination

31. Perimyocarditis references

1. Perimyocarditis in Adolescents After Pfizer-BioNTech COVID-19 Vaccine

2. Perimyocarditis in Adolescents After Pfizer-BioNTech COVID-19 Vaccine

3. Unusual Presentation of Acute Perimyocarditis After Modern SARS-COV-2 mRNA-1237 Vaccination

4. Perimyocarditis After the First Dose of mRNA-1273 SARS-CoV-2 (Moderna) Vaccine in a Young Healthy Male: Case Report

5. Acute Perimyocarditis After the First Dose of COVID-19 mRNA Vaccine

6. Perimyocarditis After Vaccination With COVID-19

7. Tinoco, M., Leite, S., Faria, B., Cardoso, S., Von Hafe, P., Dias, G., . . . Lourenco, A. (2021). Perimyocarditis Following COVID-19 Vaccination. Clin Med Insights Cardiol, 15, 11795468211056634. doi:10.1177/11795468211056634.

8. Jhaveri, R., Adler-Shohet, F. C., Blyth, C. C., Chiotos, K., Gerber, J. S., Green, M., . . . Zaoutis, T. (2021). Weighing the Risks of Perimyocarditis With the Benefits of SARS-CoV-2 mRNA Vaccination in Adolescents. J Pediatric Infect Dis Soc, 10(10), 937-939.doi:10.1093/jpids/piab061.

9. Khogali, F., & Abdelrahman, R. (2021). Unusual Presentation of Acute Perimyocarditis Following SARS-COV-2 mRNA-1237 Moderna Vaccination. Cureus, 13(7), e16590.doi:10.7759/cureus.16590.

10. Hasnie, A. A., Hasnie, U. A., Patel, N., Aziz, M. U., Xie, M., Lloyd, S. G., & Prabhu, S. D. (2021). Perimyocarditis following first dose of the mRNA-1273 SARS-CoV-2 (Moderna) vaccine in a healthy young male: a case report. BMC Cardiovasc Disord, 21(1), 375. doi:10.1186/s12872-021-02183-3

32. Petechiae references

1. Petechiae and Peeling of Fingers After Immunization with BNT162b2 Messenger RNA (mRNA)-Based COVID-19 Vaccine

2. Petechial Rash Associated with CoronaVac Vaccination: First Report of Cutaneous Side Effects Before Phase 3 Results

33. Prion Disease references

1. SARS-CoV-2, long COVID, prion disease and neurodegeneration

34. Psoriasis references

1. Onset/Outbreak of Psoriasis After Coronavirus ChAdOx1 nCoV-19 Vaccine (Oxford-AstraZeneca/Covishield): Report of Two Cases

2. Exacerbation of Plaque Psoriasis After COVID-19 Inactivated mRNA and BNT162b2 Vaccines: Report of Two Cases

3. Miller Fisher Syndrome After Pfizer COVID-19 Vaccine

4. Miller Fisher Syndrome After 2019 BNT162b2 mRNA Coronavirus Vaccination

35. Pulmonary Embolism references

1. Pulmonary Embolism, Transient Ischemic Attack, and Thrombocytopenia After Johnson & Johnson COVID-19 Vaccine

2. A Case of Acute Pulmonary Embolism After Immunization with SARS-CoV-2 mRNA

3. Isolated pulmonary embolism after COVID vaccination: 2 case reports and a review of acute pulmonary embolism complications and follow-up

4. Myocardial infarction, stroke, and pulmonary embolism after BNT162b2 mRNA COVID-19 vaccine in persons aged 75 years or older

5. Beware of neuromyelitis optica spectrum disorder after vaccination with inactivated virus for COVID-19

6. Neuromyelitis optica in a healthy woman after vaccination against severe acute respiratory syndrome coronavirus 2 mRNA-1273

7. Shingles-like skin lesion after vaccination with AstraZeneca for COVID-19: a case report

8. Recurrent herpes zoster after COVID-19 vaccination in patients with chronic urticaria on cyclosporine treatment – A report of 3 cases

36. Purpura Annularis Telangiectodes references

1. Purpuric Rash and Thrombocytopenia After mRNA-1273 (Moderna) COVID-19 Vaccine

2. Generalized Purpura Annularis Telangiectodes After SARS-CoV-2 mRNA Vaccination

37. Rhabdomyolysis references

1. Rhabdomyolysis and Fasciitis Induced by the COVID-19 mRNA Vaccine

2. COVID-19 Vaccine-Induced Rhabdomyolysis: Case Report with Literature Review

3. COVID-19 Vaccine-Induced Rhabdomyolysis: Case Report with Review of the Literature

4. Rhabdomyolysis and Fasciitis Induced by COVID-19 mRNA Vaccine

5. Case Report: ANCA-Associated Vasculitis Presenting with Rhabdomyolysis and Crescentic Pauci-Immune Glomerulonephritis After Vaccination with Pfizer-BioNTech COVID-19 mRNA

38. Systemic Lupus Erythematosus references

1. Fatal Systemic Capillary Leak Syndrome After SARS-CoV-2 Vaccination in a Patient With Multiple Myeloma

2. Systemic Capillary Extravasation Syndrome Following Vaccination with ChAdOx1 nCoV-19 (Oxford-AstraZeneca)

39. Takotsubo Cardiomyopathy references

1. Myocarditis, Pericarditis, and Cardiomyopathy After COVID-19 Vaccination

2. Takotsubo Cardiomyopathy After Vaccination with mRNA COVID-19

3. Takotsubo (Stress) Cardiomyopathy After Vaccination with ChAdOx1 nCoV-19

4. Takotsubo Cardiomyopathy After Coronavirus 2019 Vaccination in a Patient on Maintenance Hemodialysis

5. Takotsubo Syndrome After COVID-19 Vaccination

40. Thrombocytopenia References

1. Vaccine-Induced Immune Thrombotic Thrombocytopenia with Disseminated Intravascular Coagulation and Death After ChAdOx1 nCoV-19 Vaccination.

2. US Case Reports of Cerebral Venous Sinus Thrombosis with Thrombocytopenia After Vaccination with Ad26.COV2.S (against COVID-19), March 2 to April 21, 2020.

3. Management of Cerebral and Splanchnic Vein Thrombosis Associated with Thrombocytopenia in Subjects Previously Vaccinated with Vaxzevria (AstraZeneca): Position Statement of the Italian Society for the Study of Hemostasis and Thrombosis (SISET).

4. Vaccine-Induced Immune Thrombotic Thrombocytopenia and Cerebral Venous Sinus Thrombosis After Vaccination with COVID-19: A Systematic Review.

5. Thrombosis with Thrombocytopenia Syndrome Associated with COVID-19 Vaccines.

6. COVID-19 Vaccine-Induced Thrombosis and Thrombocytopenia: A Commentary on an Important and Practical Clinical Dilemma.

7. Thrombosis with Thrombocytopenia Syndrome Associated with COVID-19 Viral Vector Vaccines.

8. COVID-19 Vaccine-Induced Immune-Immune Thrombotic Thrombocytopenia: An Emerging Cause of Splanchnic Vein Thrombosis.

9. The Roles of Platelets in COVID-19-Associated Coagulopathy and Vaccine-Induced Immune Thrombotic Immune Thrombocytopenia (COVID).

10. Thrombotic Immune Thrombocytopenia Induced by SARS-CoV-2 Vaccine.

11. Thrombosis and Thrombocytopenia After Vaccination with ChAdOx1 nCoV-19.

12. Post-Mortem Findings in Vaccine-Induced Thrombotic Thrombocytopenia (COVID-19).

13. Thrombocytopenia, Including Immune Thrombocytopenia After Receiving COVID-19 mRNA Vaccines Reported to the Vaccine Adverse Event Reporting System (VAERS).

14. Hypothesis Behind the Very Rare Cases of Thrombosis with Thrombocytopenia Syndrome After SARS-CoV-2 Vaccination.

15. Primary Adrenal Insufficiency Associated with Thrombotic Immune Thrombocytopenia Induced by the Oxford-AstraZeneca ChAdOx1 nCoV-19 Vaccine (VITT).

16. Early Results of Bivalirudin Treatment for Thrombotic Thrombocytopenia and Cerebral Venous Sinus Thrombosis After Vaccination with Ad26.COV2.S.

17. Mechanisms of Immunothrombosis in Vaccine-Induced Thrombotic Thrombocytopenia (VITT) Compared to Natural SARS-CoV-2 Infection.

18. Vaccine-Induced Thrombotic Thrombocytopenia: The Dark Chapter of a Success Story.

19. Cerebral Venous Sinus Thrombosis and Thrombocytopenia After COVID-19 Vaccination: Report of Two Cases in the United Kingdom.

20. Immune Thrombocytopenic Purpura After Vaccination with COVID-19 Vaccine (ChAdOx1 nCoV-19).

21. Vaccine-Induced Thrombotic Thrombocytopenia, a Rare but Severe Case of Friendly Fire in the Battle Against the COVID-19 Pandemic: What Pathogenesis?

22. Thrombocytopenia and Intracranial Venous Sinus Thrombosis After Exposure to the “AstraZeneca COVID-19 Vaccine”

23. Thrombocytopenia Following Pfizer and Moderna SARS-CoV-2 Vaccination

24. Severe and Refractory Immune Thrombocytopenia Occurring After SARS-CoV-2 Vaccination

25. Purpuric Rash and Thrombocytopenia After mRNA-1273 (Moderna) COVID-19 Vaccine

26. Thrombosis with Thrombocytopenia After Messenger RNA Vaccine-1273

27. First Dose of ChAdOx1 and BNT162b2 COVID-19 Vaccines and Thrombocytopenic, Thromboembolic, and Hemorrhagic Events in Scotland

28. Exacerbation of Immune Thrombocytopenia After COVID-19 Vaccination

29. PF4 Immunoassays in Vaccine-Induced Thrombotic Thrombocytopenia

30. Antibody Epitopes in Vaccine-Induced Immune Thrombotic Thrombocytopenia

31. Thrombosis with Thrombocytopenia Syndrome Associated with COVID-19 Vaccines

32. Immune Thrombocytopenia Associated with Pfizer-BioNTech’s COVID-19 BNT162b2 mRNA Vaccine

33. Immune Thrombosis and Thrombocytopenia (VITT) Associated with the COVID-19 Vaccine: Diagnostic and Therapeutic Recommendations for a New Syndrome

34. Laboratory Testing for Suspicion of COVID-19 Vaccine-Induced Thrombotic (Immune) Thrombocytopenia

35. Intracerebral Haemorrhage Due to Thrombosis with Thrombocytopenia Syndrome After COVID-19 Vaccination: The First Fatal Case in Korea

36. Risk of Thrombocytopenia and Thromboembolism After COVID-19 Vaccination and Positive SARS-CoV-2 Tests: Self-Controlled Case Series Study

37. Vaccine-Induced Immune Thrombotic Thrombocytopenia and Cerebral Venous Sinus Thrombosis After COVID-19 Vaccination: A Systematic Review

38. Primary Adrenal Insufficiency Associated with Thrombotic Immune Thrombocytopenia Induced by Oxford-AstraZeneca ChAdOx1 nCoV-19 Vaccine (VITT)

39. Cerebral Venous Thrombosis and Vaccine-Induced Thrombocytopenia.a. Oxford-AstraZeneca COVID-19: A Missed Opportunity for a Rapid Return on Experience

40. Immune Thrombocytopenia in a 22-Year-Old Post COVID-19 Vaccine

41. Secondary Immune Thrombocytopenia (ITP) Associated with ChAdOx1 COVID-19 Vaccine: Case Report

42. Thrombosis with Thrombocytopenia Syndrome (TTS) Following AstraZeneca ChAdOx1 nCoV-19 (AZD1222) COVID-19 Vaccination: Risk-Benefit Analysis for Persons <60 Years in Australia

43. Bilateral Superior Ophthalmic Vein Thrombosis, Ischemic Stroke, and Immune Thrombocytopenia After Vaccination with ChAdOx1 nCoV-19

44. Risk of Thrombocytopenia and Thromboembolism After COVID-19 Vaccination and Positive SARS-CoV-2 Tests: Self-Controlled Case Series Study

45. First Dose of ChAdOx1 and BNT162b2 COVID-19 Vaccines and Thrombocytopenic, Thromboembolic, and Hemorrhagic Events in Scotland

46. Thrombocytopenia After COVID-19 Vaccination

47. A Case of Multiple Thrombocytopenia and Thrombosis Following Vaccination with ChAdOx1 nCoV-19 Against SARS-CoV-2

48. Vaccine-Induced Thrombotic Thrombocytopenia: The Elusive Link Between Thrombosis and Adenovirus-Based SARS-CoV-2 Vaccines

49. Acute Ischemic Stroke Revealing Immune Thrombotic Thrombocytopenia Induced by ChAdOx1 nCov-19 Vaccine: Impact on Recanalization Strategy

50. Procoagulant Antibody-Mediated Procoagulant Platelets in Immune Thrombotic Thrombocytopenia Associated with SARS-CoV-2 Vaccination

51. Thrombotic Thrombocytopenia After Vaccination with COVID-19: In Search of the Underlying Mechanism

52. Thrombosis and SARS-CoV-2 Vaccines: Vaccine-Induced Immune Thrombotic Thrombocytopenia

53. Acquired Thrombotic Thrombocytopenic Thrombocytopenic Purpura: A Rare Disease Associated with the BNT162b2 Vaccine

54. Immune Complexes, Innate Immunity and NETosis in ChAdOx1 Vaccine-Induced Thrombocytopenia

55. Immune-Mediated Thrombocytopenic Purpura After Pfizer-BioNTech COVID-19 Vaccine in an Elderly Woman

56. Immune-Mediated Thrombocytopenia Associated with Ad26.COV2.S Vaccine (Janssen; Johnson & Johnson)

57. Transient Thrombocytopenia with Glycoprotein-Specific Platelet Autoantibodies After Vaccination with Ad26.COV2.S: Case Report

58. COVID-19 Vaccine, Immune Thrombotic Thrombocytopenia, Jaundice, Hyperviscosity: Concern in Cases with Underlying Hepatic Problems

59. Immune Thrombocytopenia After Vaccination During the COVID-19 Pandemic

60. Vaccine-Induced Thrombocytopenia with Severe Headache

61. Vaccine-Induced Immune Thrombotic Thrombocytopenia Causing a Severe Form of Cerebral Venous Thrombosis with a High Mortality Rate: A Case Series

62. Adenovirus Interactions with Platelets and Coagulation and Vaccine-Associated Autoimmune Thrombocytopenia Thrombosis Syndrome

63. Australian and New Zealand Approach to the Diagnosis and Treatment of Vaccine-Induced Immune Thrombosis and Immune Thrombocytopenia

64. An Observational Study to Identify the Prevalence of Thrombocytopenia and Anti-PF4 / Polyanion Antibodies in Norwegian Health Care Workers After COVID-19 Vaccination

65. A Rare Case of Thrombosis and Thrombocytopenia of the Superior Ophthalmic Vein After ChAdOx1 nCoV-19 Vaccination Against SARS-CoV-2

66. Thrombosis and Severe Acute Respiratory Syndrome Coronavirus 2 Vaccines: Vaccine-Induced Immune Thrombotic Thrombocytopenia

67. Renal Vein Thrombosis and Pulmonary Embolism Secondary to Vaccine-Induced Thrombotic Immune Thrombocytopenia (VITT)

68. Limb Ischemia and Pulmonary Artery Thrombosis After ChAdOx1 nCoV-19 Vaccine (Oxford-AstraZeneca): A Case of Vaccine-Induced Immune Thrombotic Thrombocytopenia

69. A Case of Vaccine-Induced Immune-Immune Thrombotic Thrombocytopenia with Massive Arteriovenous Thrombosis

70. Thrombocytopenia in an Adolescent with Sickle Cell Anemia After COVID-19 Vaccination

71. Vaccine-Induced Thrombocytopenia with Severe Headache

72. ChAdOx1 Interacts with CAR and PF4 with Implications for Thrombosis with Thrombocytopenia Syndrome

73. Lethal Vaccine-Induced Immune Thrombotic Immune Thrombocytopenia (VITT) Following Announcement 26.COV2.S: First Documented Case Outside the U.S.

74. A Prothrombotic Thrombocytopenic Disorder Resembling Heparin-Induced Thrombocytopenia After Coronavirus-19 Vaccination

75. VITT (Vaccine-Induced Immune Thrombotic Thrombocytopenia) After Vaccination with ChAdOx1 nCoV-19

76. Vaccine-Induced Immune Thrombotic Thrombocytopenia (VITT): A New Clinicopathologic Entity with Heterogeneous Clinical Presentations

77. Treatment of Acute Ischemic Stroke Associated with ChAdOx1 nCoV-19 Vaccine-Induced Immune Thrombotic Thrombocytopenia

78. Cerebral Venous Sinus Thrombosis After Vaccination: The UK Experience

79. Cerebral Venous Vein/Venous Sinus Thrombosis with Thrombocytopenia Syndrome After COVID-19 Vaccination

80. Portal Vein Thrombosis Due to Vaccine-Induced Immune Thrombotic Immune Thrombocytopenia (VITT) After COVID Vaccination with ChAdOx1 nCoV-19

81. Spontaneous HIT Syndrome: Knee Replacement, Infection, and Parallels with Vaccine-Induced Immune Thrombotic Thrombocytopenia

82. Thrombocytopenia with Acute Ischemic Stroke and Hemorrhage in a Patient Recently Vaccinated with an Adenoviral Vector-Based COVID-19 Vaccine

83. ChAdOx1 nCoV-19 Vaccine-Associated Thrombocytopenia: Three Cases of Immune Thrombocytopenia After 107,720 Doses of ChAdOx1 Vaccination in Thailand

84. Pulmonary Embolism, Transient Ischemic Attack, and Thrombocytopenia After Johnson & Johnson COVID-19 Vaccine

85. Neurosurgical Considerations with Respect to Decompressive Craniectomy for Intracerebral Hemorrhage After SARS-CoV-2 Vaccination in Vaccine-Induced Thrombotic Thrombocytopenia-VITT

86. Secondary Thrombocytopenia After SARS-CoV-2 Vaccination: Case Report of Hemorrhage and Hematoma After Minor Oral Surgery

87. Venous Thromboembolism and Mild Thrombocytopenia After Vaccination with ChAdOx1 nCoV-19

88. Fatal Exacerbation of ChAdOx1-nCoV-19-Induced Thrombotic Thrombocytopenia Syndrome After Successful Initial Therapy with Intravenous Immunoglobulins: A Rationale for Monitoring Immunoglobulin G Levels

89. A Rare Case of COVID-19 Vaccine-Induced Thrombotic Thrombocytopenia (VITT) Affecting the Venosplanchnic and Pulmonary Arterial Circulation from a UK District General Hospital

90. COVID-19 Vaccine-Induced Thrombotic Thrombocytopenia: A Case Series

91. Immune Thrombocytopenia After Immunization with Vaxzevria ChAdOx1-S Vaccine (AstraZeneca), Victoria, Australia

92. Case Report of Immune Thrombocytopenia After Vaccination with ChAdOx1 nCoV-19

93. Thrombocytopenia with Acute Ischemic Stroke and Hemorrhage in a Patient Recently Vaccinated with an Adenoviral Vector-Based COVID-19 Vaccine

94. Intracerebral Hemorrhage and Thrombocytopenia After AstraZeneca COVID-19 Vaccine: Clinical and Diagnostic Challenges of Vaccine-Induced Thrombotic Thrombocytopenia

95. Thrombocytopenia, Including Immune Thrombocytopenia After Receiving COVID-19 mRNA Vaccines Reported to the Vaccine Adverse Event Reporting System (VAERS)

96. Newly Diagnosed Immune Thrombocytopenia in a Pregnant Patient After Coronavirus Disease 2019 Vaccination

97. Thrombocytopenia in an Adolescent with Sickle Cell Anemia After COVID-19 Vaccination

98. Abdominal Pain and Bilateral Adrenal Hemorrhage from Immune Thrombotic Thrombocytopenia Induced by COVID-19 Vaccine

99. Venous Thromboembolism and Mild Thrombocytopenia After ChAdOx1 nCoV-19 Vaccination

100. Severe Immune Thrombocytopenia Following COVID-19 Vaccination: Report of Four Cases and Review of the Literature

101. Relapse of Immune Thrombocytopenia After COVID-19 Vaccination

102. Images of Immune Thrombotic Thrombocytopenia Induced by Oxford/AstraZeneca® COVID-19 Vaccine

103. Adenovirus Interactions with Platelets and Coagulation and Vaccine-Induced Immune Thrombotic Thrombocytopenia Syndrome

104. Complicated Case Report of Long-Term Vaccine-Induced Thrombotic Immune Thrombocytopenia A

105. Prevalence of Thrombocytopenia, Anti-Platelet Factor 4 Antibodies, and Elevated D-Dimer in Thais After Vaccination with ChAdOx1 nCoV-19

106. Bilateral Thalamic Stroke: A Case of COVID-19 (VITT) Vaccine-Induced Immune Thrombotic Thrombocytopenia or a Coincidence Due to Underlying Risk Factors

107. Successful Treatment of Vaccine-Induced Immune Thrombotic Thrombocytopenia in a 26-Year-Old Female Patient

108. Case Report: Vaccine-Induced Immune Thrombotic Thrombocytopenia in a Patient with Pancreatic Cancer After Vaccination with Messenger RNA-1273

109. Vaccine-Induced Thrombotic Thrombocytopenia After Ad26.COV2.S Vaccination in a Man Presenting as Acute Venous Thromboembolism

110. Severe, Refractory Immune Thrombocytopenia Occurring After SARS-CoV-2 Vaccine

111. Risk of Thrombocytopenia and Thromboembolism After COVID-19 Vaccination and SARS-CoV-2 Positive Testing: Self-Controlled Case Series Study

112. Thrombocytopenia Following Pfizer and Moderna SARS-CoV-2 Vaccination

113. Thrombocytopenia Including Immune Thrombocytopenia After Receipt of mRNA COVID-19 Vaccines Reported to the Vaccine Adverse Event Reporting System (VAERS)

114. Relapse of Immune Thrombocytopenia After COVID-19 Vaccination in Young Male Patient

115. Peduncular, Symptomatic Cavernous Bleeding After Immune Thrombocytopenia-Induced SARS-CoV-2 Vaccination

116. Vaccine-Induced Immune Thrombotic Thrombocytopenia with Disseminated Intravascular Coagulation and Death Following the ChAdOx1 nCoV-19 Vaccine

41. Thrombosis references

1. Three Cases of Acute Venous Thromboembolism in Women After Vaccination Against COVID-19.

2. Acute Thrombosis of the Coronary Tree After Vaccination Against COVID-19.

3. US Case Reports of Cerebral Venous Sinus Thrombosis with Thrombocytopenia After Vaccination with Ad26.COV2.S (Against COVID-19), March 2 to April 21, 2020.

4. Portal Vein Thrombosis Associated with ChAdOx1 nCov-19 Vaccine.

5. Management of Cerebral and Splanchnic Vein Thrombosis Associated with Thrombocytopenia in Subjects Previously Vaccinated with Vaxzevria (AstraZeneca): Position Statement of the Italian Society for the Study of Hemostasis and Thrombosis (SISET).

6. Thrombosis With Thrombocytopenia Syndrome Associated With COVID-19 Vaccines.

7. COVID-19 Vaccine-Induced Thrombosis and Thrombocytopenia: A Commentary on an Important and Practical Clinical Dilemma.

8. Thrombosis With Thrombocytopenia Syndrome Associated With COVID-19 Viral Vector Vaccines.

9. COVID-19 Vaccine-Induced Immune-Immune Thrombotic Thrombocytopenia: An Emerging Cause of Splanchnic Vein Thrombosis.

10. The Roles of Platelets in COVID-19-Associated Coagulopathy and Vaccine-Induced Immune Thrombotic Immune Thrombocytopenia (COVID).

11. Roots of Autoimmunity of Thrombotic Events After COVID-19 Vaccination.

12. Thrombotic Immune Thrombocytopenia Induced by SARS-CoV-2 Vaccine.

13. Thrombosis and Thrombocytopenia After Vaccination with ChAdOx1 nCoV-19.

14. Thrombotic Thrombocytopenia After Vaccination with ChAdOx1 nCov-19.

15. Post-Mortem Findings in Vaccine-Induced Thrombotic Thrombocytopenia (COVID-19).

16. Comparison of Vaccine-Induced Thrombotic Episodes Between ChAdOx1 nCoV-19 and Ad26.COV.2.S Vaccines.

17. Hypothesis Behind the Very Rare Cases of Thrombosis With Thrombocytopenia Syndrome After SARS-CoV-2 Vaccination.

18. Primary Adrenal Insufficiency Associated With Thrombotic Immune Thrombocytopenia Induced by the Oxford-AstraZeneca ChAdOx1 nCoV-19 Vaccine (VITT).

19. Portal Vein Thrombosis Occurring After the First Dose of SARS-CoV-2 mRNA Vaccine in a Patient With Antiphospholipid Syndrome.

20. Early Results of Bivalirudin Treatment for Thrombotic Thrombocytopenia and Cerebral Venous Sinus Thrombosis After Vaccination With Ad26.COV2.S.

21. Mechanisms of Immunothrombosis in Vaccine-Induced Thrombotic Thrombocytopenia (VITT) Compared to Natural SARS-CoV-2 Infection.

22. Prothrombotic Immune Thrombocytopenia After COVID-19 Vaccination.

23. Vaccine-Induced Thrombotic Thrombocytopenia: The Dark Chapter of a Success Story.

24. Thrombosis After COVID-19 Vaccination: Possible Link to ACE Pathways.

25. Vaccine-Induced Thrombotic Thrombocytopenia, a Rare but Severe Case of Friendly Fire in the Battle Against the COVID-19 Pandemic: What Pathogenesis?.

26. Thrombocytopenia and Intracranial Venous Sinus Thrombosis After Exposure to the “AstraZeneca COVID-19 Vaccine”.

27. Thrombosis With Thrombocytopenia After Messenger RNA Vaccine-1273.

28. First Dose of ChAdOx1 and BNT162b2 COVID-19 Vaccines and Thrombocytopenic, Thromboembolic, and Hemorrhagic Events in Scotland.

29. PF4 Immunoassays in Vaccine-Induced Thrombotic Thrombocytopenia.

30. Antibody Epitopes in Vaccine-Induced Immune Immune Thrombotic Thrombocytopenia.

31. Thrombosis With Thrombocytopenia Syndrome Associated With COVID-19 Vaccines.

32. Immune Thrombosis and Thrombocytopenia (VITT) Associated With the COVID-19 Vaccine: Diagnostic and Therapeutic Recommendations for a New Syndrome.

33. Laboratory Testing for Suspicion of COVID-19 Vaccine-Induced Thrombotic (Immune) Thrombocytopenia.

34. Intracerebral Haemorrhage Due to Thrombosis With Thrombocytopenia Syndrome After COVID-19 Vaccination: The First Fatal Case in Korea.

35. Risk of Thrombocytopenia and Thromboembolism After COVID-19 Vaccination and Positive SARS-CoV-2 Tests: Self-Controlled Case Series Study.

36. Vaccine-Induced Immune Thrombotic Thrombocytopenia and Cerebral Venous Sinus Thrombosis After COVID-19 Vaccination; A Systematic Review.

37. Primary Adrenal Insufficiency Associated With Thrombotic Immune Thrombocytopenia Induced by Oxford-AstraZeneca ChAdOx1 nCoV-19 Vaccine (VITT).

38. Thromboaspiration Infusion and Fibrinolysis for Portomesenteric Thrombosis After Administration of AstraZeneca COVID-19 Vaccine.

39. 59-Year-Old Woman With Extensive Deep Venous Thrombosis and Pulmonary Thromboembolism 7 Days After a First Dose of Pfizer-BioNTech BNT162b2 mRNA Vaccine COVID-19.

40. Thrombosis With Thrombocytopenia Syndrome (TTS) Following AstraZeneca ChAdOx1 nCoV-19 (AZD1222) COVID-19 Vaccination: Risk-Benefit Analysis for Persons <60 Years in Australia.

41. Comparison of Vaccine-Induced Thrombotic Events Between ChAdOx1 nCoV-19 and Ad26.COV.2.S Vaccines.

42. Bilateral Superior Ophthalmic Vein Thrombosis, Ischemic Stroke and Immune Thrombocytopenia After Vaccination With ChAdOx1 nCoV-19.

43. Celiac Artery and Splenic Artery Thrombosis Complicated by Splenic Infarction 7 Days After the First Dose of Oxford Vaccine, Causal Relationship or Coincidence.

44. Primary Adrenal Insufficiency Associated With Oxford-AstraZeneca ChAdOx1 nCoV-19 (VITT) Vaccine-Induced Immune Thrombotic Thrombocytopenia.

45. Thrombosis With Thrombocytopenia Syndrome After COVID-19 Immunization.

46. Thrombosis With Thrombocytopenia Syndrome Associated With COVID-19 Viral Vector Vaccines.

47. Thromboaspiration Infusion and Fibrinolysis for Portomesenteric Thrombosis After Administration of the AstraZeneca COVID-19 Vaccine.

48. Atypical Thrombosis Associated With the Vaccine VaxZevria® (AstraZeneca): Data From the French Network of Regional Pharmacovigilance Centers.

49. Vaccine-Induced Thrombosis and Thrombocytopenia With Bilateral Adrenal Hemorrhage.

50. Palmar Digital Vein Thrombosis After Oxford-AstraZeneca COVID-19 Vaccination.

51. Cutaneous Thrombosis Associated With Cutaneous Necrosis Following Oxford-AstraZeneca COVID-19 Vaccination.

52. Thrombosis With Thrombocytopenia After Messenger Vaccine RNA-1273.

53. Coronavirus (COVID-19) Vaccine-Induced Immune Thrombotic Thrombocytopenia (VITT).

54. Comparison of Adverse Drug Reactions Among Four COVID-19 Vaccines in Europe Using the EudraVigilance Database: Thrombosis in Unusual Sites.

55. Immunoglobulin Adjuvant for Vaccine-Induced Immune Thrombotic Thrombocytopenia.

56. Severe Vaccine-Induced Thrombotic Thrombocytopenia Following Vaccination With COVID-19: An Autopsy Case Report and Review of the Literature.

57. Platelet Activation and Modulation in Thrombosis With Thrombocytopenia Syndrome Associated With the ChAdO × 1 nCov-19 Vaccine.

58. Report of the International Cerebral Venous Thrombosis Consortium on Cerebral Venous Thrombosis After SARS-CoV-2 Vaccination.

59. Immune Thrombocytopenia Associated With the Pfizer-BioNTech COVID-19 mRNA Vaccine BNT162b2.

60. Secondary Immune Thrombocytopenia Putatively Attributable to COVID-19 Vaccination.

61. Immune Thrombocytopenia Following Pfizer-BioNTech BNT162b2 mRNA COVID-19 Vaccine.

62. Newly Diagnosed Idiopathic Thrombocytopenia After COVID-19 Vaccine Administration.

63. Idiopathic Thrombocytopenic Purpura and the Modern COVID-19 Vaccine.

64. Thrombocytopenia After Pfizer and Moderna SARS-CoV-2 Vaccination.

65. Immune Thrombocytopenic Purpura and Acute Liver Injury After COVID-19 Vaccination.

66. Carotid Artery Immune Thrombosis Induced by Adenovirus-Vectored COVID-19 Vaccine: Case Report.

67. The Roles of Platelets in COVID-19-Associated Coagulopathy and Vaccine-Induced Immune-Thrombotic Thrombocytopenia.

68. Cerebral Venous Sinus Thrombosis Negative for Anti-PF4 Antibody Without Thrombocytopenia After Immunization With COVID-19 Vaccine in a Non-Comorbid Elderly Indian Male Treated With Conventional Heparin-Warfarin-Based Anticoagulation.

69. Arterial Events, Venous Thromboembolism, Thrombocytopenia, and Bleeding After Vaccination With Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway: Population-Based Cohort Study.

70. Procoagulant Microparticles: A Possible Link Between Vaccine-Induced Immune Thrombocytopenia (VITT) and Cerebral Sinus Venous Thrombosis.

71. U.S. Case Reports of Cerebral Venous Sinus Thrombosis With Thrombocytopenia After Vaccination With Ad26.COV2.S, March 2-April 21, 2021.

72. Malignant Cerebral Infarction After Vaccination With ChAdOx1 nCov-19: A Catastrophic Variant of Vaccine-Induced Immune-Mediated Thrombotic Thrombocytopenia.

73. Acute Ischemic Stroke Revealing Immune Thrombotic Thrombocytopenia Induced by ChAdOx1 nCov-19 Vaccine: Impact on Recanalization Strategy.

74. Vaccine-Induced Immune Thrombotic Immune Thrombocytopenia (VITT): A New Clinicopathologic Entity With Heterogeneous Clinical Presentations.

75. Imaging and Hematologic Findings in Thrombosis and Thrombocytopenia After Vaccination With ChAdOx1 nCoV-19 (AstraZeneca).

76. Autoimmunity Roots of Thrombotic Events After Vaccination With COVID-19.

77. Cerebral Venous Sinus Thrombosis After Vaccination: The UK Experience.

78. Cutaneous Thrombosis Associated With Cutaneous Necrosis Following Oxford-AstraZeneca COVID-19 Vaccination.

79. Myocardial Infarction and Azygos Vein Thrombosis After Vaccination With ChAdOx1 nCoV-19 in a Hemodialysis Patient.

80. Refractory Vaccine-Induced Immune Thrombotic Thrombocytopenia (VITT) Treated With Delayed Therapeutic Plasma Exchange (TPE).

81. Rare Case of COVID-19 Vaccine-Associated Intracranial Hemorrhage With Venous Sinus Thrombosis.

82. Delayed Headache After COVID-19 Vaccination: A Warning Sign for Vaccine-Induced Cerebral Venous Thrombosis.

83. Clinical Features of Vaccine-Induced Thrombocytopenia and Immune Thrombosis.

84. Predictors of Mortality in Thrombotic Thrombocytopenia After Adenoviral COVID-19 Vaccination: The FAPIC Score.

85. Ischemic Stroke as a Presenting Feature of Immune Thrombotic Thrombocytopenia Induced by ChAdOx1-nCoV-19 Vaccination.

86. Endovascular Treatment for Vaccine-Induced Cerebral Venous Sinus Thrombosis and Thrombocytopenia After Vaccination with ChAdOx1 nCoV-19: Report of Three Cases.

87. Possible Triggers of Thrombocytopenia and/or Hemorrhage by BNT162b2 Vaccine, Pfizer-BioNTech.

88. Multiple Sites of Arterial Thrombosis in a 35-Year-Old Patient After Vaccination With ChAdOx1 (AstraZeneca), Which Required Emergency Femoral and Carotid Surgical Thrombectomy.

89. Case Series of Vaccine-Induced Thrombotic Thrombocytopenia in a London Teaching Hospital.

90. Neuro-Ophthalmic Complications With Thrombocytopenia and Thrombosis Induced by ChAdOx1 nCoV-19 Vaccine.

91. Thrombotic Events After COVID-19 Vaccination in Over 50 Years of Age: Results of a Population-Based Study in Italy.

92. Intracerebral Hemorrhage Associated With Vaccine-Induced Thrombotic Thrombocytopenia After ChAdOx1 nCOVID-19 Vaccination in a Pregnant Woman.

93. Age- and Sex-Specific Incidence of Cerebral Venous Sinus Thrombosis Associated With Ad26.COV2.S COVID-19 Vaccination.

94. Genital Necrosis With Cutaneous Thrombosis Following Vaccination With COVID-19 mRNA.

95. Cerebral Venous Sinus Thrombosis After mRNA-Based COVID-19 Vaccination.

96. COVID-19 Vaccine-Induced Immune Thrombosis With Thrombocytopenia Thrombosis (VITT) and Shades of Gray in Thrombus Formation.

97. Acute ST-Segment Elevation Myocardial Infarction Secondary to Vaccine-Induced Immune Thrombosis With Thrombocytopenia (VITT).

98. Thrombosis With Thrombocytopenia Syndrome (TTS) After Vaccination With AstraZeneca ChAdOx1 nCoV-19 (AZD1222) COVID-19: A Risk-Benefit Analysis for Persons <60 Years in Australia.

99. Characteristics and Outcomes of Patients With Cerebral Venous Sinus Thrombosis in Thrombotic Immune Thrombocytopenia Induced by SARS-CoV-2 Vaccine.

100. Case Study of Thrombosis and Thrombocytopenia Syndrome After Administration of the AstraZeneca COVID-19 Vaccine.

101. Thrombosis with Thrombocytopenia Syndrome Associated with COVID-19 Vaccines.

102. Cerebral Venous Sinus Thrombosis Following Vaccination with ChAdOx1: The First Case of Definite Thrombosis with Thrombocytopenia Syndrome in India.

103. COVID-19 Vaccine-Associated Thrombosis with Thrombocytopenia Syndrome (TTS): Systematic Review and Post Hoc Analysis.

104. Concerns for Adverse Effects of Thrombocytopenia and Thrombosis After Adenovirus-Vectored COVID-19 Vaccination.

105. Cerebral Venous Sinus Thrombosis After COVID-19 Vaccination: Neurologic and Radiologic Management.

106. Case Report: Cerebral Sinus Vein Thrombosis in Two Patients with AstraZeneca SARS-CoV-2 Vaccine.

107. Vaccine-Induced Immune Thrombosis and Thrombocytopenia Syndrome After Adenovirus-Vectored Severe Acute Respiratory Syndrome Coronavirus 2 Vaccination: A New Hypothesis on Mechanisms and Implications for Future Vaccine Development.

108. Thrombosis in Peripheral Artery Disease and Thrombotic Thrombocytopenia Following Adenoviral COVID-19 Vaccination.

109. Cerebral Venous Sinus Thrombosis and Thrombotic Events After Vector-Based COVID-19 Vaccines: Systematic Review and Meta-Analysis.

110. Thrombosis After COVID-19 Vaccination: Possible Link to ACE Pathways.

111. Major Artery Thrombosis and Vaccination Against ChAdOx1 nCov-19.

112. Understanding the Risk of Thrombosis with Thrombocytopenia Syndrome Following Ad26.COV2.S Vaccination.

113. Comments on Thrombosis After Vaccination: Spike Protein Leader Sequence Could Be Responsible for Thrombosis and Antibody-Mediated Thrombocytopenia.

114. Thrombosis in Pre- and Post-Vaccination Phase of COVID-19.

115. Vaccine-Associated Thrombocytopenia and Thrombosis: Venous Endotheliopathy Leading to Combined Venous Micro-Macrothrombosis.

116. Thrombosis and Thrombocytopenia Syndrome Causing Isolated Symptomatic Carotid Occlusion After COVID-19 Ad26.COV2.S Vaccine (Janssen).

117. An Unusual Presentation of Acute Deep Vein Thrombosis After Modern COVID-19 Vaccine: Case Report.

118. Immediate High-Dose Intravenous Immunoglobulins Followed by Direct Treatment With Thrombin Inhibitors Is Crucial for Survival in Vaccine-Induced Immune Thrombotic Thrombocytopenia SARS-Covid-19-Vector Adenoviral VITT With Venous Thrombosis of the Cerebral Sinus and Portal Vein.

119. Thrombosis Formation After COVID-19 Vaccination Immunologic Aspects: Review Article.

120. Imaging and Hematologic Findings in Thrombosis and Thrombocytopenia After Vaccination With ChAdOx1 nCoV-19 (AstraZeneca).

121. Cerebral Venous Sinus Thrombosis, Pulmonary Embolism, and Thrombocytopenia After COVID-19 Vaccination in a Taiwanese Man: A Case Report and Review of the Literature.

122. Fatal Cerebral Venous Sinus Thrombosis After COVID-19 Vaccination.

123. Autoimmune Roots of Thrombotic Events After COVID-19 Vaccination.

124. New Portal Vein Thrombosis in Cirrhosis: Is Thrombophilia Exacerbated by Vaccine or COVID-19.

125. Cerebral Venous Sinus Thrombosis After Vaccination With COVID-19 mRNA of BNT162b2.

126. A Case of Unusual Mild Clinical Presentation of COVID-19 Vaccine-Induced Immune Thrombotic Thrombocytopenia With Splanchnic Vein Thrombosis.

127. Cerebral Venous Sinus Thrombosis Following Vaccination With Pfizer-BioNTech COVID-19 (BNT162b2).

128. A Case of Idiopathic Thrombocytopenic Purpura After a Booster Dose of COVID-19 BNT162b2 Vaccine (Pfizer-Biontech).

129. Vaccine-Induced Immune Thrombotic Immune Thrombocytopenia (VITT): Targeting Pathologic Mechanisms With Bruton’s Tyrosine Kinase Inhibitors.

130. Thromboembolic Events in Younger Females Exposed to Pfizer-BioNTech or Moderna COVID-19 Vaccines.

131. Thrombosis After Adenovirus-Vectored COVID-19 Vaccination: A Concern for Underlying Disease.

132. Unusual Site of Deep Vein Thrombosis After Vaccination Against Coronavirus mRNA-2019 Coronavirus Disease (COVID-19).

133. Deep Venous Thrombosis After Vaccination With Ad26.COV2.S in Adult Males.

134. Clinical and Biological Features of Cerebral Venous Sinus Thrombosis After Vaccination With ChAdOx1 nCov-19.

135. COV2-S Vaccination May Reveal Hereditary Thrombophilia: Massive Cerebral Venous Sinus Thrombosis in a Young Man With Normal Platelet Count.

136. Post-mortem Findings in Vaccine-Induced Thrombotic Thrombocytopenia.

137. COVID-19 Vaccine-Induced Thrombosis.

138. Inflammation and Platelet Activation After COVID-19 Vaccines: Possible Mechanisms Behind Vaccine-Induced Immune Thrombocytopenia and Thrombosis.

139. Anaphylactoid Reaction and Coronary Thrombosis Related to COVID-19 mRNA Vaccine.

140. Occurrence of Splenic Infarction Due to Arterial Thrombosis After Vaccination With COVID-19.

141. Deep Venous Thrombosis More Than Two Weeks After COVID-19 Vaccination.

142. Information on ChAdOx1 nCoV-19 Vaccine-Induced Immune-Mediated Thrombotic Thrombocytopenia.

143. Management of a Patient With a Rare Congenital Limb Malformation Syndrome After SARS-CoV-2 Vaccine-Induced Thrombosis and Thrombocytopenia (VITT).

144. Thrombocytopenia and Splanchnic Thrombosis After Vaccination With Ad26.COV2.S Successfully Treated With Transjugular Intrahepatic Portosystemic Shunt and Thrombectomy.

145. Chang, J. C., & Hawley, H. B. (2021). Vaccine-Associated Thrombocytopenia and Thrombosis: Venous Endotheliopathy Leading to Venous Combined Micro-Macrothrombosis. Medicina (Kaunas), 57(11). doi:10.3390/medicina57111163.

146. Potential Risk of Thrombotic Events After COVID-19 Vaccination With Oxford-AstraZeneca in Women Receiving Estrogen.

147. Thrombotic Adverse Events Reported for Moderna, Pfizer, and Oxford-AstraZeneca COVID-19 Vaccines: Comparison of Occurrence and Clinical Outcomes in the EudraVigilance Database.

148. Predicted and Observed Incidence of Thromboembolic Events Among Koreans Vaccinated With the ChAdOx1 nCoV-19 Vaccine.

149. Three Cases of Acute Venous Thromboembolism in Women After Coronavirus 2019 Vaccination.

150. Shazley, O., & Alshazley, M. (2021). A COVID-Positive 52-Year-Old Man Presented With Venous Thromboembolism and Disseminated Intravascular Coagulation Following Johnson & Johnson Vaccination: A Case-Study. Cureus, 13(7), e16383.doi:10.7759/cureus.16383.

42. Thrombotic Thrombocytopenic Purpura references

1. Thrombotic Thrombocytopenic Purpura after Vaccination with Ad26.COV2-S

2. Thrombotic Thrombocytopenic Purpura: A New Threat after COVID BNT162b2 Vaccine

3. Severe Immune Thrombocytopenic Purpura after SARS-CoV-2 Vaccine

4. Immune Thrombocytopenic Purpura Associated with COVID-19 mRNA Vaccine Pfizer-BioNTech BNT16B2b2

43. Vasculitis References

1. ANCA-Associated Vasculitis After Pfizer-BioNTech COVID-19 Vaccine

2. Propylthiouracil-Induced Neutrophil Anti-Cytoplasmic Antibody-Associated Vasculitis After COVID-19 Vaccination

3. IgA Vasculitis in Adult Patient After Vaccination with ChAdOx1 nCoV-19

4. A Case of Leukocytoclastic Vasculitis After Vaccination with a SARS-CoV2 Vaccine: Case Report

5. A Case of ANCA-Associated Vasculitis After AZD1222 (Oxford-AstraZeneca) SARS-CoV-2 Vaccination: Victim or Causality?

6. Leukocytoclastic Vasculitis as a Cutaneous Manifestation of ChAdOx1 Corona Virus Vaccine nCoV-19 (Recombinant)

7. Induction of Cutaneous Leukocytoclastic Vasculitis After ChAdOx1 nCoV-19 Vaccine

8. Recurrent ANCA-Associated Vasculitis After Oxford AstraZeneca ChAdOx1-S COVID-19 Vaccination: A Case Series of Two Patients

9. Cutaneous Lymphocytic Vasculitis After Administration of the Second Dose of AZD1222 (Oxford-AstraZeneca) Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine: Chance or Causality

10. Case Report: Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis with Acute Renal Failure and Pulmonary Hemorrhage Can Occur After COVID-19 Vaccination

11. Intracerebral Hemorrhage Due to Vasculitis Following COVID-19 Vaccination: Case Report

12. COVID-19 Vaccine-Induced Urticarial Vasculitis

13. ANCA-Associated Vasculitis After Pfizer-BioNTech COVID-19 Vaccine

14. New-Onset Leukocytoclastic Vasculitis After COVID-19 Vaccine

15. Cutaneous Small Vessel Vasculitis After COVID-19 Vaccine

16. Outbreak of Leukocytoclastic Vasculitis After COVID-19 Vaccine

17. Leukocytoclastic Vasculitis After Exposure to COVID-19 Vaccine

18. Vasculitis and Bursitis in [18F] FDG-PET/CT After COVID-19 mRNA Vaccine: Post Hoc Ergo Propter Hoc?

19. Cutaneous Lymphocytic Vasculitis After Administration of COVID-19 mRNA Vaccine

20. Cutaneous Leukocytoclastic Vasculitis Induced by Sinovac COVID-19 Vaccine

21. Reactivation of IgA Vasculitis After Vaccination with COVID-19

22. Varicella-Zoster Virus-Related Small-Vessel Vasculitis After Pfizer-BioNTech COVID-19 Vaccination

23. Imaging in Vascular Medicine: Leukocytoclastic Vasculitis After COVID-19 Vaccine Booster

24. Cutaneous Vasculitis Following COVID-19 Vaccination

25. Possible Case of COVID-19 mRNA Vaccine-Induced Small-Vessel Vasculitis

26. IgA Vasculitis Following COVID-19 Vaccination in an Adult

27. Propylthiouracil-Induced Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis Following Vaccination with COVID-19

28. Coronavirus Disease Vaccine 2019 (COVID-19) in Systemic Lupus Erythematosus and Neutrophil Anti-Cytoplasmic Antibody-Associated Vasculitis

29. Reactivation of IgA Vasculitis After COVID-19 Vaccination

30. First Description of Immune Complex Vasculitis After COVID-19 Vaccination with BNT162b2: Case Report

31. Nephrotic Syndrome and Vasculitis After SARS-CoV-2 Vaccine: True Association or Circumstantial

32. Occurrence of De Novo Cutaneous Vasculitis After Vaccination Against Coronavirus Disease (COVID-19)

33. Asymmetric Cutaneous Vasculitis After COVID-19 Vaccination with Unusual Preponderance of Eosinophils

34. Granulomatous Vasculitis After AstraZeneca Anti-SARS-CoV-2 Vaccine

35. A Case of Generalized Sweet’s Syndrome with Vasculitis Triggered by Recent Vaccination with COVID-19

36. Small-Vessel Vasculitis Following Oxford-AstraZeneca Vaccination Against SARS-CoV-19

37. Cutaneous Vasculitis After Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine

38. Leukocytoclastic Vasculitis After Coronavirus Disease Vaccination 2019

39. Outbreaks of Mixed Cryoglobulinemia Vasculitis After Vaccination Against SARS-CoV-2

40. Cutaneous Small-Vessel Vasculitis After Vaccination with a Single Dose of Janssen Ad26.COV2.S

41. Case of Immunoglobulin A Vasculitis After Vaccination Against Coronavirus Disease 2019

42. Relapse of Microscopic Polyangiitis After COVID-19 Vaccination: Case Report

44. Vogt-Koyanagi-Harada Syndrome references

1. Vogt-Koyanagi-Harada Syndrome After COVID-19 and ChAdOx1 nCoV-19 (AZD1222) Vaccination

2. Reactivation of Vogt-Koyanagi-Harada Disease Under Control for More Than 6 Years, After Anti-SARS-CoV-2 Vaccination